Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Inflammatory Bowel Diseases

  Free Subscription


Articles published in J Crohns Colitis

Retrieve available abstracts of 519 articles:
HTML format
Text format



Single Articles


    December 2018
  1. LOVISA S, Genovese G, Danese S
    Role of epithelial-to-mesenchymal transition in inflammatory bowel disease.
    J Crohns Colitis. 2018 Dec 6. pii: 5231866. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. VEGNI E, Gilardi D, Bonovas S, Corro BE, et al
    Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study.
    J Crohns Colitis. 2018 Dec 4. pii: 5230943. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2018
  3. GROSEN A, Bungum M, Christensen LA, Cordelli E, et al
    Semen Quality and Sperm DNA Integrity in Patients With Severe Active Inflammatory Bowel Disease and Effects of Tumour Necrosis Factor-alpha Inhibitors.
    J Crohns Colitis. 2018 Nov 30. pii: 5219032. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. FORKEL M, van Tol S, Hoog C, Michaelsson J, et al
    Distinct Alterations in the Composition of Mucosal Innate Lymphoid Cells in Newly Diagnosed and Established Crohn's Disease and Ulcerative Colitis.
    J Crohns Colitis. 2018 Nov 29. pii: 5215151. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. KUCHARZIK T, Maaser C, Maconi G
    Do We Need Activity Scores or Simply Clear Criteria for Intestinal Ultrasound in Ulcerative Colitis?
    J Crohns Colitis. 2018;12:1383-1384.
    PubMed     Text format    


  6. DE JONG MJ, Roosen D, Degens JHRJ, van den Heuvel TRA, et al
    Development and validation of a patient-reported score to screen for mucosal inflammation in inflammatory bowel disease.
    J Crohns Colitis. 2018 Nov 24. pii: 5205616. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. WALSH A, Kormilitzin A, Hinds C, Sexton V, et al
    Defining faecal calprotectin thresholds as a surrogate for endoscopic and histological disease activity in ulcerative colitis - a prospective analysis.
    J Crohns Colitis. 2018 Nov 16. pii: 5184629. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. ZAKRZEWSKI M, Simms LA, Brown A, Appleyard M, et al
    IL23R-protective coding variant promotes beneficial bacteria and diversity in the ileal microbiome in healthy individuals without inflammatory bowel disease.
    J Crohns Colitis. 2018 Nov 16. pii: 5184638. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. BENOIT L, Mir O, Berveiller P
    Treating ulcerative colitis during pregnancy: evidence of materno-fetal transfer of golimumab.
    J Crohns Colitis. 2018 Nov 15. pii: 5183381. doi: 10.1093.
    PubMed     Text format    


  10. LEARY A, Mason I, Punshon G
    Modelling the Inflammatory Bowel Disease Specialist Nurse Workforce Standards by Determination of Optimum Caseloads in the UK.
    J Crohns Colitis. 2018;12:1295-1301.
    PubMed     Text format     Abstract available


  11. DENG F, He S, Cui S, Shi Y, et al
    A Molecular Targeted Immunotherapeutic Strategy for Ulcerative Colitis via Dual-Targeting Nanoparticles Delivering miR-146b to Intestinal Macrophages.
    J Crohns Colitis. 2018 Nov 15. pii: 5184562. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. DI NARZO AF, Brodmerkel C, Telesco SE, Argmann C, et al
    High Throughput Identification of Plasma Proteomic Signature of Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Nov 15. pii: 5183355. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. WEN KW, Rabinovitch PS, Wang D, Huang D, et al
    Utility of DNA Flow Cytometric Analysis of Paraffin-Embedded Tissue in the Risk Stratification and Management of "Indefinite for Dysplasia" in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Nov 13. pii: 5180116. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. FIORINO G, Allocca M, Chaparro M, Coenen S, et al
    'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review.
    J Crohns Colitis. 2018 Nov 13. pii: 5181323. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. AMBROSE T, Simmons A
    Cannabis, cannabinoids and the endocannabinoid system - is there therapeutic potential for inflammatory bowel disease?
    J Crohns Colitis. 2018 Nov 12. pii: 5173479. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. PANES J, Vermeire S, Lindsay JO, Sands BE, et al
    Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
    J Crohns Colitis. 2018 Nov 8. pii: 5167345. doi: 10.1093.
    PubMed     Text format    


  17. DAI C, Jiang M, Huang YH
    Appendectomy for Therapy-Refractory Ulcerative Colitis Results in Pathological Improvement of Colonic Inflammation.
    J Crohns Colitis. 2018 Nov 5. pii: 5161247. doi: 10.1093.
    PubMed     Text format    


  18. NYHOLM I, Hukkinen M, Koivusalo A, Merras-Salmio L, et al
    Long-term single center outcomes after proctocolectomy with ileoanal anastomosis for paediatric ulcerative colitis.
    J Crohns Colitis. 2018 Nov 3. pii: 5160018. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. LOUIS E
    Do we still need predictors of disease severity when applying a treat-to-target approach in Inflammatory Bowel Disease?
    J Crohns Colitis. 2018 Nov 2. pii: 5156178. doi: 10.1093.
    PubMed     Text format    


    October 2018
  20. WINTJENS DSJ, de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, et al
    Novel perceived stress and life events precede flares of inflammatory bowel disease: a prospective 12-month follow-up study.
    J Crohns Colitis. 2018 Oct 29. pii: 5146297. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. BALRAM B, Battat R, Al-Khoury A, D'Aoust J, et al
    Reply to Letter on: "Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis".
    J Crohns Colitis. 2018 Oct 29. pii: 5146063. doi: 10.1093.
    PubMed     Text format    


  22. ALFARO-CRUZ L, Schady D, Kellermayer R
    Giant cell (granulomatous) gastritis in left sided pediatric ulcerative colitis.
    J Crohns Colitis. 2018 Oct 23. pii: 5142539. doi: 10.1093.
    PubMed     Text format    


  23. CLOS-PARALS A, Rodriguez-Martinez P, Canete F, Manosa M, et al
    Prognostic value of the burden of cytomegalovirus colonic reactivation evaluated by immunohistochemical staining in patients with active ulcerative colitis.
    J Crohns Colitis. 2018 Oct 20. pii: 5139670. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. LAMPINEN M, Vessby J, Fredricsson A, Wanders A, et al
    High serum sCD40 and a distinct colonic T-cell profile in ulcerative colitis associated with primary sclerosing cholangitis.
    J Crohns Colitis. 2018 Oct 20. pii: 5139660. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. STELLINGWERF ME, de Koning MA, Pinkney T, Bemelman WA, et al
    The risk of colectomy and colorectal cancer after appendectomy in patients with ulcerative colitis: a systematic review and meta-analysis.
    J Crohns Colitis. 2018 Oct 18. pii: 5136376. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. MAGRO F, Dias CC, Portela F, Miranda M, et al
    Development and validation of risk matrices concerning ulcerative colitis outcomes - Bayesian network analysis.
    J Crohns Colitis. 2018 Oct 17. pii: 5133622. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. LOREN V, Garcia-Jaraquemada A, Naves JE, Carmona X, et al
    ANP32E, a protein involved in steroid-refractoriness in ulcerative colitis, identified by a systems biology approach.
    J Crohns Colitis. 2018 Oct 17. pii: 5134087. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. AARESTRUP J, Jess T, Kobylecki CJ, Nordestgaard BG, et al
    Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of >100,000 individuals.
    J Crohns Colitis. 2018 Oct 13. pii: 5128952. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. NGUYEN GC, Bouchard S, Diong C
    Access to Specialists and Emergency Department Visits in Inflammatory Bowel Disease: A Population-Based Study.
    J Crohns Colitis. 2018 Oct 12. pii: 5127082. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. DAI C, Jiang M, Huang YH
    Risk factors associated with Clostridium difficile infection in inflammatory bowel disease.
    J Crohns Colitis. 2018 Oct 12. pii: 5127329. doi: 10.1093.
    PubMed     Text format    


  31. MEGE D, Colombo F, Stellingwerf ME, Germain A, et al
    Risk factors for small bowel obstruction after laparoscopic ileal pouch-anal anastomosis for inflammatory bowel disease. A multivariate analysis in 4 expert centres in Europe.
    J Crohns Colitis. 2018 Oct 11. pii: 5127081. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. GISBERT JP, Chaparro M
    Clinical usefulness of proteomics in inflammatory bowel disease: A comprehensive review.
    J Crohns Colitis. 2018 Oct 10. pii: 5126442. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. MACALUSO FS, Fries W, Privitera AC, Cappello M, et al
    A propensity score-matched comparison of infliximab and adalimumab in TNF-alpha inhibitors naive and non-naive patients with Crohn's disease: real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).
    J Crohns Colitis. 2018 Oct 6. pii: 5122861. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. BURISCH J, Katsanos KH, Christodoulou DK, Barros L, et al
    Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study.
    J Crohns Colitis. 2018 Oct 5. pii: 5115808. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. ARMUZZI A, Avedano L, Greveson K, Kang T, et al
    Nurses are critical in aiding patients transitioning to biosimilars in inflammatory bowel disease: education and communication strategies.
    J Crohns Colitis. 2018 Oct 4. pii: 5114647. doi: 10.1093.
    PubMed     Text format     Abstract available


  36. SANDBORN WJ, Colombel JF, Panaccione R, Dulai PS, et al
    Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis.
    J Crohns Colitis. 2018 Oct 4. pii: 5114646. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. FELICE C, Armuzzi A
    Therapeutic role of appendectomy in ulcerative colitis: a tangible perspective?
    J Crohns Colitis. 2018 Oct 3. pii: 5114385. doi: 10.1093.
    PubMed     Text format    


  38. SAHAMI S, Wildenberg ME, Koens L, Doherty G, et al
    Appendectomy for Therapy-Refractory Ulcerative Colitis Results in Pathological Improvement of Colonic Inflammation: Short-Term Results of the PASSION Study.
    J Crohns Colitis. 2018 Oct 3. pii: 5114636. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. DUNSMORE G, Koleva P, Ghobakhloo N, Sutton RT, et al
    Lower Abundance and Impaired Function of CD71+ Erythroid Cells in Inflammatory Bowel Disease Patients During Pregnancy.
    J Crohns Colitis. 2018 Oct 1. pii: 5113167. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. KREDEL LI, Jodicke LJ, Scheffold A, Grone J, et al
    T-cell composition in ileal and colonic creeping fat - separating ileal from colonic Crohn s disease.
    J Crohns Colitis. 2018 Oct 1. pii: 5113232. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2018
  41. TRIVEDI PJ, Adams DH
    Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise.
    J Crohns Colitis. 2018 Sep 29. pii: 5111299. doi: 10.1093.
    PubMed     Text format    


  42. WONG JJ, Sceats L, Dehghan M, Wren AA, et al
    Depression and Healthcare Utilization in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Sep 25. pii: 5106946. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. BALRAM B, Battat R, Al-Khoury A, D'Aoust J, et al
    Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis.
    J Crohns Colitis. 2018 Sep 21. pii: 5104729. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. PEREIRA MS, Maia L, Azevedo LF, Campos S, et al
    A (glyco)biomarker that predicts failure to standard therapy in Ulcerative Colitis patients.
    J Crohns Colitis. 2018 Sep 20. pii: 5104327. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. VAN HOEVE K, Dreesen E, Hoffman I, Van Assche G, et al
    Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Sep 19. pii: 5103494. doi: 10.1093.
    PubMed     Text format     Abstract available


  46. KIERNAN MG, Coffey JC, McDermott K, Cotter PD, et al
    The human mesenteric lymph node microbiome differentiates between Crohn's disease and ulcerative colitis.
    J Crohns Colitis. 2018 Sep 15. pii: 5098279. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. CHAN W, Shim HH, Ng SC, Liu J, et al
    A Global Survey of Gastroenterologists' Travel Advice to Patients with Inflammatory Bowel Disease on Immunosuppressive Agents and Management of Those Visiting Tuberculosis-Endemic Areas.
    J Crohns Colitis. 2018 Sep 11. pii: 5095284. doi: 10.1093.
    PubMed     Text format     Abstract available


  48. SVRCEK M, Borralho Nunes PM, Villanacci V, Beaugerie L, et al
    Clinicopathological and molecular specificities of inflammatory bowel disease-related colorectal neoplastic lesions: the role of inflammation.
    J Crohns Colitis. 2018 Sep 10. pii: 5094505. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. VLEUGELS JLA, Rutter MD, Ragunath K, Rees CJ, et al
    Diagnostic accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for lesion characterisation in ulcerative colitis surveillance: ETMI or chromoendoscopy for lesion characterisation in colitis.
    J Crohns Colitis. 2018 Sep 8. pii: 5092911. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. FEAGAN BG, Sandborn WJ, Colombel JF, O'Byrne S, et al
    Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials.
    J Crohns Colitis. 2018 Sep 3. pii: 5089953. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2018
  51. ARTOM M, Czuber-Dochan W, Sturt J, Norton C, et al
    Corrigendum: Targets for Health Interventions for Inflammatory Bowel Disease-fatigue.
    J Crohns Colitis. 2018 Aug 28. pii: 5085555. doi: 10.1093.
    PubMed     Text format    


  52. STURM A, Maaser C, Calabrese E, Annese V, et al
    ECCO-ESGAR Guideline for Diagnostic Assessment in Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Aug 23. pii: 5078200. doi: 10.1093.
    PubMed     Text format    


  53. MAASER C, Sturm A, Vavricka SR, Kucharzik T, et al
    ECCO-ESGAR Guideline for Diagnostic Assessment in Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Aug 23. pii: 5078195. doi: 10.1093.
    PubMed     Text format    


  54. PANES J, Salas A
    Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
    J Crohns Colitis. 2018;12.
    PubMed     Text format     Abstract available


  55. RIVERA-NIEVES J
    Targeting leukocyte traffic: A new era for the treatment of Inflammatory bowel disease.
    J Crohns Colitis. 2018;12.
    PubMed     Text format    


  56. TRIVEDI PJ, Adams DH
    Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise.
    J Crohns Colitis. 2018;12.
    PubMed     Text format     Abstract available


  57. TAMAN H, Fenton CG, Hensel IV, Anderssen E, et al
    Genome-Wide DNA Methylation in Treatment-Naive Ulcerative Colitis.
    J Crohns Colitis. 2018 Aug 22. pii: 5077493. doi: 10.1093.
    PubMed     Text format     Abstract available


  58. GUI X, Li J, Ueno A, Iacucci M, et al
    Histopathologic Features of Inflammatory Bowel Disease are Associated with Different CD4+ T Cell Subsets in Colonic Mucosal Lamina Propria.
    J Crohns Colitis. 2018 Aug 20. pii: 5076882. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. RICCIUTO A, Dhaliwal J, Walters TD, Griffiths AM, et al
    Clinical outcomes with therapeutic drug monitoring in inflammatory bowel disease: A systematic review with meta-analysis.
    J Crohns Colitis. 2018 Aug 10. pii: 5068814. doi: 10.1093.
    PubMed     Text format     Abstract available


  60. ALLOCCA M, Fiorino G, Bonovas S, Furfaro F, et al
    Accuracy of Humanitas Ultrasound Criteria in assessing disease activity and severity in ulcerative colitis: a prospective study.
    J Crohns Colitis. 2018 Aug 4. pii: 5066493. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  61. TAXONERA C, Ponferrada A, Riestra S, Bermejo F, et al
    Serial Tuberculin Skin Tests Improves the Detection of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Jul 21. pii: 5056955. doi: 10.1093.
    PubMed     Text format     Abstract available


  62. PROBERT F, Walsh A, Jagielowicz M, Yeo T, et al
    Plasma Nuclear Magnetic Resonance metabolomics discriminates between high and low endoscopic activity and predicts progression in a prospective cohort of patients with ulcerative colitis.
    J Crohns Colitis. 2018 Jul 17. pii: 5054826. doi: 10.1093.
    PubMed     Text format     Abstract available


  63. ESTEVINHO MM, Afonso J, Rosa I, Lago P, et al
    Placebo effect on the health-related quality of life of inflammatory bowel disease patients: a systematic review with meta-analysis.
    J Crohns Colitis. 2018 Jul 14. pii: 5053906. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  64. VAN DER HAVE M, Oldenburg B, Kaptein AA, Jansen JM, et al
    Corrigendum: Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.
    J Crohns Colitis. 2018 Jun 30. pii: 5047411. doi: 10.1093.
    PubMed     Text format    


  65. STEIN J, Aksan A, Klemm W, Nip K, et al
    Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
    J Crohns Colitis. 2018;12:826-834.
    PubMed     Text format     Abstract available


  66. DE BRUYN JR, van den Brink GR, Steenkamer J, Buskens CJ, et al
    Fibrostenotic Phenotype of Myofibroblasts in Crohn's Disease is Dependent on Tissue Stiffness and Reversed by LOX Inhibition.
    J Crohns Colitis. 2018;12:849-859.
    PubMed     Text format     Abstract available


  67. WARDLE RA, Thapaliya G, Nowak A, Radford S, et al
    An Examination of Appetite and Disordered Eating in Active Crohn's Disease.
    J Crohns Colitis. 2018;12:819-825.
    PubMed     Text format     Abstract available


  68. RISPO A, Imperatore N, Testa A, Bucci L, et al
    Combined Endoscopic/Sonographic-based Risk Matrix Model for Predicting One-year Risk of Surgery: A Prospective Observational Study of a Tertiary Centre Severe/Refractory Crohn's Disease Cohort.
    J Crohns Colitis. 2018;12:784-793.
    PubMed     Text format     Abstract available


  69. BONOVAS S, Peyrin-Biroulet L, Danese S
    Meta-analysis of the Association between anti-TNF use and Lymphoma Risk in Patients with Inflammatory bowel Disease: Methodological Considerations.
    J Crohns Colitis. 2018 Jun 27. pii: 5045852. doi: 10.1093.
    PubMed     Text format    


  70. OZAKI R, Kobayashi T, Okabayashi S, Nakano M, et al
    Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis with Endoscopically Normal Mucosa.
    J Crohns Colitis. 2018 Jun 25. pii: 5043543. doi: 10.1093.
    PubMed     Text format     Abstract available


  71. CUSHING KC, Kordbacheh H, Gee MS, Kambadakone A, et al
    Reply to "Comment on Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients".
    J Crohns Colitis. 2018 Jun 23. pii: 5043266. doi: 10.1093.
    PubMed     Text format    


  72. COSTA JM, Carvalho SD, Soares JB
    Mesalazine-induced Bronchiolitis Obliterans with Organizing Pneumonia in a young patient with Ulcerative Colitis.
    J Crohns Colitis. 2018 Jun 20. pii: 5040612. doi: 10.1093.
    PubMed     Text format    


  73. REINISCH W, Gibson PR, Sandborn WJ, Feagan BG, et al
    Long-term Benefit of Golimumab for Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.
    J Crohns Colitis. 2018 Jun 18. pii: 5039659. doi: 10.1093.
    PubMed     Text format     Abstract available


  74. GROSEN A, Nersting J, Bungum M, Christensen LA, et al
    Sperm DNA Integrity is Unaffected by Thiopurine Treatment in Men with Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Jun 16. pii: 5039596. doi: 10.1093.
    PubMed     Text format     Abstract available


  75. IHARA S, Hirata Y, Hikiba Y, Yamashita A, et al
    Adhesive interactions between Mononuclear Phagocytes and Intestinal Epithelium Perturb Normal Epithelial Differentiation and Serve as a Therapeutic Target in Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Jun 16. pii: 5039593. doi: 10.1093.
    PubMed     Text format     Abstract available


  76. SANDS BE, Sandborn WJ, Feagan BG, Lichtenstein GR, et al
    Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2 Study.
    J Crohns Colitis. 2018 Jun 15. pii: 5038906. doi: 10.1093.
    PubMed     Text format     Abstract available


  77. LEE HS, Yang SK, Hong M, Jung S, et al
    An intergenic variant rs9268877 between HLA-DRA and HLA-DRB contributes to the clinical course and long-term outcome of ulcerative colitis.
    J Crohns Colitis. 2018 Jun 13. pii: 5037295. doi: 10.1093.
    PubMed     Text format     Abstract available


  78. IRANI NR, Wang LM, Collins GS, Keshav S, et al
    Correlation between Endoscopic and Histological Activity in Ulcerative Colitis using Validated Indices.
    J Crohns Colitis. 2018 Jun 11. pii: 5035459. doi: 10.1093.
    PubMed     Text format     Abstract available


  79. BINAY SAFER V, Safer U
    Comment on "Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients".
    J Crohns Colitis. 2018 Jun 9. pii: 5035236. doi: 10.1093.
    PubMed     Text format    


    May 2018
  80. GUIDI L, Pugliese D, Panici Tonucci T, Berrino A, et al
    Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study.
    J Crohns Colitis. 2018 May 31. pii: 5026188. doi: 10.1093.
    PubMed     Text format     Abstract available


  81. PAUL S, Williet N, Di Bernado T, Berger AE, et al
    Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
    J Crohns Colitis. 2018 May 31. pii: 5026191. doi: 10.1093.
    PubMed     Text format     Abstract available


  82. KANG B, Choi SY, Choi YO, Kim MJ, et al
    Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn's Disease Patients Treated With Combined Immunosuppressive Therapy.
    J Crohns Colitis. 2018;12:644-652.
    PubMed     Text format     Abstract available


  83. REUKEN PA, Kruis W, Maaser C, Teich N, et al
    Microbial Spectrum of Intra-Abdominal Abscesses in Perforating Crohn's Disease: Results from a Prospective German Registry.
    J Crohns Colitis. 2018;12:695-701.
    PubMed     Text format     Abstract available


  84. WRIGHT EK, Kamm MA, De Cruz P, Hamilton AL, et al
    Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease.
    J Crohns Colitis. 2018;12:653-661.
    PubMed     Text format     Abstract available


  85. SINGH S, George J, Boland BS, Vande Casteele N, et al
    Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2018;12:635-643.
    PubMed     Text format     Abstract available


  86. WAGNER M, Ko HM, Chatterji M, Besa C, et al
    Magnetic Resonance Imaging Predicts Histopathological Composition of Ileal Crohn's Disease.
    J Crohns Colitis. 2018;12:718-729.
    PubMed     Text format     Abstract available


  87. BELVIS JIMENEZ M, Maldonado Perez B, Arguelles-Arias F
    Using Vedolizumab to treat Severe Sweet's Syndrome in a Patient with Ulcerative Colitis.
    J Crohns Colitis. 2018 May 19. pii: 4999769. doi: 10.1093.
    PubMed     Text format    


  88. FEAGAN BG, Bhayat F, Khalid M, Blake A, et al
    Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials.
    J Crohns Colitis. 2018 May 17. pii: 4997031. doi: 10.1093.
    PubMed     Text format     Abstract available


  89. LAMB CA, O'Byrne S, Keir ME, Butcher EC, et al
    Gut-selective integrin-targeted therapies for inflammatory bowel disease.
    J Crohns Colitis. 2018 May 15. pii: 4996111. doi: 10.1093.
    PubMed     Text format     Abstract available


  90. SANDBORN WJ, Bhandari BR, Randall C, Younes ZH, et al
    Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.
    J Crohns Colitis. 2018 May 14. pii: 4996034. doi: 10.1093.
    PubMed     Text format     Abstract available


  91. CUSHING KC, Kordbacheh H, Gee MS, Kambadakone A, et al
    Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients.
    J Crohns Colitis. 2018 May 12. pii: 4995527. doi: 10.1093.
    PubMed     Text format     Abstract available


  92. YANG C, Huang J, Huang X, Huang S, et al
    Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2018 May 12. pii: 4995526. doi: 10.1093.
    PubMed     Text format     Abstract available


  93. LEE CK, Wong SH, Lui G, Tang W, et al
    A prospective study to monitor for tuberculosis during anti-tumour necrosis factor therapy in patients with inflammatory bowel disease and immune mediated inflammatory diseases.
    J Crohns Colitis. 2018 May 11. pii: 4994967. doi: 10.1093.
    PubMed     Text format     Abstract available


  94. FOBELO LOZANO MJ, Serrano Gimenez R, Castro Fernandez M
    Emergence of Inflammatory Bowel Disease During Treatment with Secukinumab.
    J Crohns Colitis. 2018 May 9. pii: 4994228. doi: 10.1093.
    PubMed     Text format     Abstract available


  95. COHEN-MEKELBURG S, Rosenblatt R, Gold S, Burakoff R, et al
    The Impact of Opioid Epidemic Trends on Hospitalized Inflammatory Bowel Disease Patients.
    J Crohns Colitis. 2018 May 7. pii: 4993358. doi: 10.1093.
    PubMed     Text format     Abstract available


  96. TSE CS, Deepak P, De La Fuente J, Bledsoe AC, et al
    Phenotype and Clinical Course of Inflammatory Bowel Disease with Co-Existent Celiac Disease.
    J Crohns Colitis. 2018 May 7. pii: 4993346. doi: 10.1093.
    PubMed     Text format     Abstract available


  97. GARG M, Hendy P, Ding JN, Shaw S, et al
    The effect of vitamin D on intestinal inflammation and faecal microbiota in patients with ulcerative colitis.
    J Crohns Colitis. 2018 May 3. pii: 4991883. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  98. LAW CCY, Narula A, Lightner AL, McKenna NP, et al
    Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2018;12:538-545.
    PubMed     Text format     Abstract available


  99. YARLAS A, Rubin DT, Panes J, Lindsay JO, et al
    Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36(R) Health Survey.
    J Crohns Colitis. 2018;12:600-609.
    PubMed     Text format     Abstract available


  100. FEAGAN BG, Schwartz D, Danese S, Rubin DT, et al
    Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2.
    J Crohns Colitis. 2018;12:621-626.
    PubMed     Text format     Abstract available


  101. HOEKMAN DR, Stibbe JA, Baert FJ, Caenepeel P, et al
    Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease.
    J Crohns Colitis. 2018;12:517-524.
    PubMed     Text format     Abstract available


  102. VISSCHEDIJK MC, Spekhorst LM, Cheng SC, van Loo ES, et al
    Genomic and Expression Analyses Identify a Disease-Modifying Variant for Fibrostenotic Crohn's Disease.
    J Crohns Colitis. 2018;12:582-588.
    PubMed     Text format     Abstract available


  103. BORREN NZ, Conway G, Garber JJ, Khalili H, et al
    Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases.
    J Crohns Colitis. 2018;12:525-531.
    PubMed     Text format     Abstract available


  104. WINTJENS DSJ, Bogie RMM, van den Heuvel TRA, le Clercq CMC, et al
    Incidence and classification of postcolonoscopy colorectal cancers in inflammatory bowel disease: A Dutch population-based cohort study.
    J Crohns Colitis. 2018 Apr 10. pii: 4965889. doi: 10.1093.
    PubMed     Text format     Abstract available


  105. WANG Z, Zhang W, Luo C, Zhu M, et al
    Primary Intestinal Epstein-Barr Virus-associated Natural killer/T-Cell Lymphoproliferative Disorder: A Disease Mimicking Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Apr 7. pii: 4964706. doi: 10.1093.
    PubMed     Text format     Abstract available


  106. KEVANS D, Murthy S, Mould DR, Silverberg MS, et al
    Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.
    J Crohns Colitis. 2018 Apr 6. pii: 4963864. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  107. PARRAGI L, Fournier N, Zeitz J, Scharl M, et al
    Colectomy Rates in Ulcerative Colitis Are Low and Decreasing: 10-year-follow-up Data from the Swiss IBD Cohort Study.
    J Crohns Colitis. 2018 Mar 31. pii: 4957044. doi: 10.1093.
    PubMed     Text format     Abstract available


  108. KOELINK PJ, Wildenberg ME, Stitt LW, Feagan BG, et al
    Development of Reliable, Valid and Responsive Scoring Systems for Endoscopy and Histology in Animal Models for Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Mar 28. pii: 4955731. doi: 10.1093.
    PubMed     Text format     Abstract available


  109. SNOWDEN JA, Panes J, Alexander T, Allez M, et al
    Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT.
    J Crohns Colitis. 2018;12:476-488.
    PubMed     Text format     Abstract available


  110. GREENER T, Boland K, Steinhart AH, Silverberg MS, et al
    The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn's Disease.
    J Crohns Colitis. 2018;12:458-464.
    PubMed     Text format     Abstract available


  111. LIGHTNER AL, McKenna NP, Tse CS, Hyman N, et al
    Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease.
    J Crohns Colitis. 2018;12:402-407.
    PubMed     Text format     Abstract available


  112. HIRAI F, Andoh A, Ueno F, Watanabe K, et al
    Efficacy of Endoscopic Balloon Dilation for Small Bowel Strictures in Patients With Crohn's Disease: A Nationwide, Multi-centre, Open-label, Prospective Cohort Study.
    J Crohns Colitis. 2018;12:394-401.
    PubMed     Text format     Abstract available


  113. PAPAMICHAEL K, Vajravelu RK, Vaughn BP, Osterman MT, et al
    Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease.
    J Crohns Colitis. 2018 Mar 24. pii: 4953445. doi: 10.1093.
    PubMed     Text format     Abstract available


  114. HONG M, Ye BD, Yang SK, Jung S, et al
    Immunochip meta-analysis of inflammatory bowel disease identifies three novel loci and four novel associations in previously reported loci.
    J Crohns Colitis. 2018 Mar 23. pii: 4951970. doi: 10.1093.
    PubMed     Text format     Abstract available


  115. LEDDER O, Assa A, Levine A, Escher JC, et al
    Corrigendum: Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
    J Crohns Colitis. 2018 Mar 17. pii: 4942346. doi: 10.1093.
    PubMed     Text format    


  116. KANG JE, Kim HD, Park SY, Pan JG, et al
    Dietary Supplementation with a Bacillus Superoxide Dismutase Protects Against gamma-Radiation-induced Oxidative Stress and Ameliorates Dextran Sulfate Sodium-induced Ulcerative Colitis in Mice.
    J Crohns Colitis. 2018 Mar 14. pii: 4935132. doi: 10.1093.
    PubMed     Text format     Abstract available


  117. LEE S, Metcalfe A, Raman M, Leung Y, et al
    Pregnant Women with Inflammatory Bowel Disease are at Increased Risk of Vitamin D Insufficiency: A Cross-Sectional Study.
    J Crohns Colitis. 2018 Mar 13. pii: 4931216. doi: 10.1093.
    PubMed     Text format     Abstract available


  118. CHEN T, Zhou Q, Zhang D, Jiang F, et al
    Effect of Faecal Microbiota Transplantation for Treatment of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Cohort Studies.
    J Crohns Colitis. 2018 Mar 8. pii: 4924729. doi: 10.1093.
    PubMed     Text format     Abstract available


  119. OTTAVIANO G, Salvatore S, Salvatoni A, Martelossi S, et al
    Ocular Manifestations of Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2018 Mar 6. pii: 4922546. doi: 10.1093.
    PubMed     Text format     Abstract available


  120. KEMP K, Dibley L, Chauhan U, Greveson K, et al
    2nd N-ECCO Consensus Statements on the European Nursing Roles in Caring for Patients with Crohn's Disease or Ulcerative Colitis.
    J Crohns Colitis. 2018 Mar 2. pii: 4917790. doi: 10.1093.
    PubMed     Text format    


    February 2018
  121. LO B, Vester-Andersen MK, Vind I, Prosberg M, et al
    Changes in Disease Behaviour and Location in Patients With Crohn's Disease After Seven Years of Follow-Up: A Danish Population-based Inception Cohort.
    J Crohns Colitis. 2018;12:265-272.
    PubMed     Text format     Abstract available


  122. ROTTOLI M, Vallicelli C, Bigonzi E, Gionchetti P, et al
    Prepouch Ileitis After Ileal Pouch-anal Anastomosis: Patterns of Presentation and Risk Factors for Failure of Treatment.
    J Crohns Colitis. 2018;12:273-279.
    PubMed     Text format     Abstract available


  123. WANG Y, Gao X, Ghozlane A, Hu H, et al
    Characteristics of Faecal Microbiota in Paediatric Crohn's Disease and Their Dynamic Changes During Infliximab Therapy.
    J Crohns Colitis. 2018;12:337-346.
    PubMed     Text format     Abstract available


  124. KLANG E, Amitai MM, Lahat A, Yablecovitch D, et al
    Capsule Endoscopy Validation of the Magnetic Enterography Global Score in Patients with Established Crohn's Disease.
    J Crohns Colitis. 2018;12:313-320.
    PubMed     Text format     Abstract available


  125. COHEN-DOLEV N, Sladek M, Hussey S, Turner D, et al
    Differences in Outcomes Over Time With Exclusive Enteral Nutrition Compared With Steroids in Children With Mild to Moderate Crohn's Disease: Results From the GROWTH CD Study.
    J Crohns Colitis. 2018;12:306-312.
    PubMed     Text format     Abstract available


  126. BESWICK L, Rosella O, Rosella G, Headon B, et al
    Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study.
    J Crohns Colitis. 2018;12:289-297.
    PubMed     Text format     Abstract available


  127. SRINIVASAN A, Vasudevan A, McFarlane A, Sparrow MP, et al
    Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn's Disease.
    J Crohns Colitis. 2018;12:280-288.
    PubMed     Text format     Abstract available


  128. ROWAN CR, Cullen G, Mulcahy HE, Keegan D, et al
    Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation.
    J Crohns Colitis. 2018;12:376-378.
    PubMed     Text format     Abstract available


  129. LAMBDIN J, Rowe A, Borum M
    Physical Activity and Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Feb 27. pii: 4911522. doi: 10.1093.
    PubMed     Text format    


  130. DOMENECH E, Panes J, Hinojosa J, Annese V, et al
    "Addition of granulocyte/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: A randomized, multicentre, clinical trial".
    J Crohns Colitis. 2018 Feb 27. pii: 4911562. doi: 10.1093.
    PubMed     Text format     Abstract available


  131. NIELSEN OH, Rejnmark L, Moss AC
    Role of Vitamin D in the Natural History of Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Feb 24. pii: 4908651. doi: 10.1093.
    PubMed     Text format     Abstract available



  132. Corrigendum: Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists.
    J Crohns Colitis. 2018 Feb 21. pii: 4883181. doi: 10.1093.
    PubMed     Text format    


  133. MORENO MARQUEZ C, Maldonado Perez B, Castro Laria L
    Infliximab as rescue treatment in a Sweet's Syndrome related to corticodependent ulcerative colitis.
    J Crohns Colitis. 2018 Feb 21. pii: 4883175. doi: 10.1093.
    PubMed     Text format    


  134. MOHAMMADI A, Kelly OB, Filice M, Kabakchiev B, et al
    Differential expression of microRNAs in peripheral blood mononuclear cells identifies autophagy and TGF-beta related signatures aberrantly expressed in inflammatory bowel disease.
    J Crohns Colitis. 2018 Feb 6. pii: 4840562. doi: 10.1093.
    PubMed     Text format     Abstract available


  135. BURISCH J, Gisbert JP, Siegmund B, Bettenworth D, et al
    Validation of the "United Registries for Clinical Assessment and Research" (UR-CARE), a European online registry for clinical care and research in Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Feb 3. pii: 4836265. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  136. ROSARIO M, French JL, Dirks NL, Sankoh S, et al
    Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
    J Crohns Colitis. 2018 Jan 29. pii: 4828071. doi: 10.1093.
    PubMed     Text format    


  137. RAKNES G, Simonsen P, Smabrekke L
    The effect of Low Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental before-and-after Prescription Database Study.
    J Crohns Colitis. 2018 Jan 27. pii: 4827597. doi: 10.1093.
    PubMed     Text format     Abstract available


  138. LAHIFF C, Wang LM, Travis SPL, East JE, et al
    Diagnostic Yield of Dysplasia in Polyp-Adjacent Biopsies for Patients with Inflammatory Bowel Disease: A Cross-Sectional Study.
    J Crohns Colitis. 2018 Jan 27. pii: 4827063. doi: 10.1093.
    PubMed     Text format     Abstract available


  139. LASERNA-MENDIETA EJ, Clooney AG, Carretero-Gomez JF, Moran C, et al
    Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut Microbiome in Crohn's Disease and Ulcerative Colitis.
    J Crohns Colitis. 2018;12:204-216.
    PubMed     Text format     Abstract available


  140. ANDERSEN V, Chan S, Luben R, Khaw KT, et al
    Fibre intake and the development of inflammatory bowel disease: A European prospective multi-centre cohort study (EPIC-IBD).
    J Crohns Colitis. 2018;12:129-136.
    PubMed     Text format     Abstract available


  141. ENGEL T, Ungar B, Yung DE, Ben-Horin S, et al
    Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis.
    J Crohns Colitis. 2018;12:245-257.
    PubMed     Text format     Abstract available


  142. GUIZZETTI L, Zou G, Khanna R, Dulai PS, et al
    Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease.
    J Crohns Colitis. 2018;12:167-177.
    PubMed     Text format     Abstract available


  143. D'HAENS G, Vermeire S, Vogelsang H, Allez M, et al
    Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating beta7+ T Cells in Crohn's Disease: Report of the TOSCA Study.
    J Crohns Colitis. 2018;12:188-196.
    PubMed     Text format     Abstract available


  144. THOMAS C, Monteil-Ganiere C, Mirallie S, Hemont C, et al
    A Severe Neonatal Lymphopenia Associated With Administration of Azathioprine to the Mother in a Context of Crohn's Disease.
    J Crohns Colitis. 2018;12:258-261.
    PubMed     Text format     Abstract available


  145. ZHU Z, Mei Z, Guo Y, Wang G, et al
    Reduced Risk of Inflammatory Bowel Disease-associated Colorectal Neoplasia with Use of Thiopurines: a Systematic Review and Meta-analysis.
    J Crohns Colitis. 2018 Jan 23. pii: 4822002. doi: 10.1093.
    PubMed     Text format     Abstract available


  146. BOSSUYT P, Debeuckelaere C, Ferrante M, de Buck van Overstraeten A, et al
    Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk Model.
    J Crohns Colitis. 2018;12:32-38.
    PubMed     Text format     Abstract available


  147. ORLANDO S, Fraquelli M, Coletta M, Branchi F, et al
    Ultrasound Elasticity Imaging Predicts Therapeutic Outcomes of Patients With Crohn's Disease Treated With Anti-Tumour Necrosis Factor Antibodies.
    J Crohns Colitis. 2018;12:63-70.
    PubMed     Text format     Abstract available


  148. HASSAN-ZAHRAEE M, Banerjee A, Cheng JB, Zhang W, et al
    Anti-MAdCAM Antibody Increases ss7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn's Disease.
    J Crohns Colitis. 2018;12:77-86.
    PubMed     Text format     Abstract available


  149. SALVADOR P, Macias-Ceja DC, Gisbert-Ferrandiz L, Hernandez C, et al
    CD16+ Macrophages Mediate Fibrosis in Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Jan 3. pii: 4783136. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  150. VIDE J, Osorio F, Costa-Silva M, Lopes S, et al
    Cutaneous morbidity among inflammatory bowel disease patients: a cohort study.
    J Crohns Colitis. 2017 Dec 28. pii: 4781052. doi: 10.1093.
    PubMed     Text format     Abstract available


  151. DE BOER NKH, Peyrin-Biroulet L, Jharap B, Sanderson JD, et al
    Thiopurines in Inflammatory Bowel Disease: new findings and perspectives.
    J Crohns Colitis. 2017 Dec 25. pii: 4774531. doi: 10.1093.
    PubMed     Text format     Abstract available


  152. DAI C, Jiang M, Cao Q
    Steroid and the risk of venous thromboembolic events in inflammatory bowel disease.
    J Crohns Colitis. 2017 Dec 23. pii: 4774286. doi: 10.1093.
    PubMed     Text format    


  153. MCDERMOTT E, Healy G, Mullen G, Keegan D, et al
    Patient education in inflammatory bowel disease; a patient-centred, mixed methodology study.
    J Crohns Colitis. 2017 Dec 23. pii: 4773946. doi: 10.1093.
    PubMed     Text format     Abstract available


  154. POUILLON L, Peyrin-Biroulet L
    It is time to revise the STRIDE guidelines determining therapeutic goals for treat-to-target in inflammatory bowel disease.
    J Crohns Colitis. 2017 Dec 23. pii: 4773849. doi: 10.1093.
    PubMed     Text format    


  155. BRAGA NETO MB, Gregory M, Piovezani Ramos G, Loftus EV Jr, et al
    De-novo Inflammatory bowel disease after bariatric surgery: a large case series.
    J Crohns Colitis. 2017 Dec 20. pii: 4767779. doi: 10.1093.
    PubMed     Text format     Abstract available


  156. KONO M, Komeda Y, Sakurai T, Okamoto A, et al
    Induction of complete remission by azacitidine in a patient with myelodysplastic syndrome-associated inflammatory bowel disease.
    J Crohns Colitis. 2017 Dec 14. pii: 4743180. doi: 10.1093.
    PubMed     Text format     Abstract available


  157. ROMKENS TEH, Kranenburg P, van Tilburg A, Bronkhorst C, et al
    Assessment of histological remission in ulcerative colitis: discrepancies between daily practice and expert opinion.
    J Crohns Colitis. 2017 Dec 12. pii: 4733426. doi: 10.1093.
    PubMed     Text format     Abstract available


  158. HEIDA A, Dijkstra A, Muller Kobold A, Rossen J, et al
    The efficacy of home telemonitoring versus conventional follow-up: a randomised controlled trial among teenagers with inflammatory bowel disease.
    J Crohns Colitis. 2017 Dec 8. pii: 4710333. doi: 10.1093.
    PubMed     Text format     Abstract available


  159. LOPEZ RN, Gupta N, Lemberg DA
    Vedolizumab-associated pancreatitis in paediatric ulcerative colitis - functional selectivity of the alpha4beta7integrin and MAdCAM-1 pathway?
    J Crohns Colitis. 2017 Dec 8. pii: 4712095. doi: 10.1093.
    PubMed     Text format    


  160. ALAMEEL T, Mosli MH
    Combination therapy with adalimumab and thiopurines in inflammatory bowel disease. Is it a case of nepotism in pharmacology?
    J Crohns Colitis. 2017 Dec 6. pii: 4694420. doi: 10.1093.
    PubMed     Text format    


  161. SARLOS P, Szemes K, Hegyi P, Garami A, et al
    Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease. A meta-analysis.
    J Crohns Colitis. 2017 Dec 6. pii: 4694102. doi: 10.1093.
    PubMed     Text format     Abstract available


  162. KIM AH, Roberts C, Feagan BG, Banerjee R, et al
    Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease - an International, Cross-disciplinary Consensus.
    J Crohns Colitis. 2017 Dec 5. pii: 4694039. doi: 10.1093.
    PubMed     Text format     Abstract available


  163. SMIDS C, Horjus Talabur Horje CS, Drylewicz J, Roosenboom B, et al
    Intestinal T cell profiling in Inflammatory Bowel Disease; linking T cell subsets to disease activity and disease course.
    J Crohns Colitis. 2017 Dec 4. pii: 4689802. doi: 10.1093.
    PubMed     Text format     Abstract available


  164. ONOUFRIADIS A, Stone K, Katsiamides A, Amar A, et al
    Exome sequencing and genotyping identify a rare variant in NLRP7 gene associated with ulcerative colitis.
    J Crohns Colitis. 2017 Dec 4. pii: 4689794. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  165. HENRIKSEN M, Hoivik ML, Jelsness-Jorgensen LP, Moum B, et al
    Irritable bowel-like symptoms in ulcerative colitis are as common in patients in deep remission as with inflammation; results from a population-based study (the IBSEN study).
    J Crohns Colitis. 2017 Nov 27. pii: 4668347. doi: 10.1093.
    PubMed     Text format     Abstract available


  166. VAVRICKA SR, Galvan JA, Dawson H, Soltermann A, et al
    Expression Patterns of TNFalpha, MAdCAM1 and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Nov 22. pii: 4647660. doi: 10.1093.
    PubMed     Text format     Abstract available


  167. MOGENSEN DV, Brynskov J, Ainsworth MA, Nersting J, et al
    A role for thiopurine metabolites in the synergism between thiopurines and infliximab in inflammatory bowel disease.
    J Crohns Colitis. 2017 Nov 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  168. PAGNINI C, Mariani BM, Lorenzetti R
    Ulcerative Colitis Endoscopic Index of Severity is feasible and useful for endoscopic activity evaluation in ulcerative colitis patients in real-life setting.
    J Crohns Colitis. 2017 Nov 14. doi: 10.1093.
    PubMed     Text format    


    October 2017
  169. HARBORD M, Eliakim R, Bettenworth D, Karmiris K, et al
    Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.
    J Crohns Colitis. 2017 Oct 21. doi: 10.1093.
    PubMed     Text format    


  170. TAMAN H, Fenton CG, Hensel IV, Anderssen E, et al
    Transcriptomic Landscape of Treatment - Naive Ulcerative Colitis.
    J Crohns Colitis. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  171. ANIWAN S, Tremaine WJ, Raffals LE, Kane SV, et al
    Antibiotic use and new-onset inflammatory bowel disease in Olmsted County, Minnesota: a population-based case-control study.
    J Crohns Colitis. 2017 Sep 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  172. NORDENVALL C, Rosvall O, Bottai M, Everhov AH, et al
    Surgical treatment in childhood-onset inflammatory bowel disease -A nationwide register-based study of 4,695 incident patients in Sweden 2002-2014.
    J Crohns Colitis. 2017 Sep 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  173. DEDERICHS F, Iesalnieks I, Sladek M, Tzivinikos C, et al
    Genital granulomatosis in male and female patients with Crohn`s disease: clinical presentation and treatment outcomes.
    J Crohns Colitis. 2017 Sep 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  174. PANES J, Vermeire S, Lindsay JO, Sands BE, et al
    Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomized Controlled Induction and Maintenance Studies.
    J Crohns Colitis. 2017 Sep 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  175. VANHOVE W, Nys K, Arijs I, Cleynen I, et al
    Biopsy-derived intestinal epithelial cell cultures for pathway based stratification of patients with inflammatory bowel disease.
    J Crohns Colitis. 2017 Sep 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  176. OSSUM AM, Palm O, Lunder AK, Cvancarova M, et al
    Ankylosing spondylitis and axial spondyloarthritis in patients with long-term inflammatory bowel disease: Results from 20 years of follow-up in the IBSEN study.
    J Crohns Colitis. 2017 Sep 13. doi: 10.1093.
    PubMed     Text format     Abstract available


  177. ASSA A, Rinawi F, Shamir R
    The long-term predictive properties of the Paris classification in pediatric inflammatory bowel disease patients.
    J Crohns Colitis. 2017 Sep 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  178. HOSOMI S, Yamagami H, Itani S, Yukawa T, et al
    Sepsis markers soluble IL-2 receptor and soluble CD14 subtype as potential biomarkers for complete mucosal healing in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017 Sep 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  179. SHI HY, Chan FKL, Chan AWH, Higashimori A, et al
    Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores.
    J Crohns Colitis. 2017;11:1071-1077.
    PubMed     Text format     Abstract available


  180. SINGH A, Agrawal N, Kurada S, Lopez R, et al
    Efficacy, Safety, and Long-term Outcome of Serial Endoscopic Balloon Dilation for Upper Gastrointestinal Crohn's Disease-associated Strictures-A Cohort Study.
    J Crohns Colitis. 2017;11:1044-1051.
    PubMed     Text format     Abstract available


  181. CONNORS J, Basseri S, Grant A, Giffin N, et al
    Exclusive Enteral Nutrition Therapy in Paediatric Crohn's Disease Results in Long-term Avoidance of Corticosteroids: Results of a Propensity-score Matched Cohort Analysis.
    J Crohns Colitis. 2017;11:1063-1070.
    PubMed     Text format     Abstract available


  182. WESTEROUEN VAN MEETEREN MJ, Hayee B, Inderson A, van der Meulen AE, et al
    Safety of Anti-TNF Treatment in Liver Transplant Recipients: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2017;11:1146-1151.
    PubMed     Text format     Abstract available


  183. FELDBRUGGE L, Moss AC, Yee EU, Csizmadia E, et al
    Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease.
    J Crohns Colitis. 2017;11:1113-1123.
    PubMed     Text format     Abstract available


  184. BIRIMBERG-SCHWARTZ L, Zucker DM, Akriv A, Cucchiara S, et al
    Development and Validation of Diagnostic Criteria for IBD Subtypes Including IBD-unclassified in Children: a Multicentre Study From the Pediatric IBD Porto Group of ESPGHAN.
    J Crohns Colitis. 2017;11:1078-1084.
    PubMed     Text format     Abstract available


  185. SMIDS C, Horjus Talabur Horje CS, Nierkens S, Drylewicz J, et al
    Candidate Serum Markers in Early Crohn's Disease: Predictors of Disease Course.
    J Crohns Colitis. 2017;11:1090-1100.
    PubMed     Text format     Abstract available


  186. CATALAN-SERRA I, Sandvik AK, Bruland T, Andreu-Ballester JC, et al
    Gammadelta T Cells in Crohn's Disease: A New Player in the Disease Pathogenesis?
    J Crohns Colitis. 2017;11:1135-1145.
    PubMed     Text format     Abstract available


    August 2017
  187. NAKARAI A, Hiraoka S, Takahashi S, Inaba T, et al
    Simultaneous measurements of fecal calprotectin and the fecal immunochemical test in quiescent ulcerative colitis patients can stratify risk of relapse.
    J Crohns Colitis. 2017 Aug 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  188. LAHAT A, Shitrit AB, Naftali T, Milgrom Y, et al
    Vedolizumab levels in breast milk of nursing mothers with inflammatory bowel disease.
    J Crohns Colitis. 2017 Aug 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  189. HINDRYCKX P, Vande Casteele N, Novak G, Khanna R, et al
    The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?
    J Crohns Colitis. 2017 Aug 25. doi: 10.1093.
    PubMed     Text format     Abstract available



  190. Corrigendum: Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Aug 23. doi: 10.1093.
    PubMed     Text format    


  191. ZHANG M, Xu C, Liu D, Han MK, et al
    Oral delivery of nanoparticles loaded with ginger active compound, 6-shogaol, attenuates ulcerative colitis and promotes wound healing in a murine model of ulcerative colitis.
    J Crohns Colitis. 2017 Aug 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  192. SIGALL-BONEH R, Levine A, Lomer M, Wierdsma N, et al
    Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group (Dietitians of ECCO).
    J Crohns Colitis. 2017 Aug 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  193. MARK-CHRISTENSEN A, Erichsen R, Brandsborg S, Rosenberg J, et al
    Long-term Risk of Cancer Following Ileal Pouch-anal Anastomosis for Ulcerative Colitis.
    J Crohns Colitis. 2017 Aug 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  194. WILKENS R, Hagemann-Madsen RH, Peters DA, Nielsen AH, et al
    Validity of Contrast Enhanced Ultrasonography and Dynamic Contrast Enhanced MR Enterography in the Assessment of Transmural Activity and Fibrosis in Crohn s Disease.
    J Crohns Colitis. 2017 Aug 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  195. DOHERTY G, Katsanos KH, Burisch J, Allez M, et al
    European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ('Exit Strategies') in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Aug 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  196. TURNER D, Carle A, Steiner SJ, Margolis PA, et al
    Quality Items Required for Running a Paediatric Inflammatory Bowel Disease Centre: An ECCO Paper.
    J Crohns Colitis. 2017;11:981-987.
    PubMed     Text format     Abstract available


    July 2017
  197. DANESE S, Furfaro F, Vetrano S
    Targeting S1P in Inflammatory bowel disease: new avenues for modulating intestinal leukocyte migration.
    J Crohns Colitis. 2017 Jul 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  198. LEUNG CM, Tang W, Moe K, Niamul G, et al
    Endoscopic and Histologic Mucosal Healing in Ulcerative Colitis in the First Year of Diagnosis: Results from a Population-based Inception Cohort from Six Countries in Asia.
    J Crohns Colitis. 2017 Jul 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  199. CASANOVA MJ, Chaparro M, Molina B, Merino O, et al
    Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Jul 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  200. RIVIERE P, Zallot C, Desobry P, Sabate JM, et al
    Frequency of and Factors Associated With Sexual Dysfunction in Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Jul 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  201. SPEKHORST LM, Severs M, de Boer NKH, Festen EAM, et al
    The Impact of Ethnicity and Country of Birth on Inflammatory Bowel Disease Phenotype: a Prospective Cohort Study.
    J Crohns Colitis. 2017 Jul 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  202. MORAR PS, Hollingshead J, Bemelman W, Sevdalis N, et al
    Establishing Key Performance Indicators [KPIs] and Their Importance for the Surgical Management of Inflammatory Bowel Disease-Results From a Pan-European, Delphi Consensus Study.
    J Crohns Colitis. 2017 Jul 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  203. TRAVIS S, Feagan BG, Peyrin-Biroulet L, Panaccione R, et al
    Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA.
    J Crohns Colitis. 2017 Jul 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  204. LAMB CA, Kirby JA, Keir ME, Mansfield JC, et al
    T Lymphocytes Expressing AlphaE Beta7 Integrin in Ulcerative Colitis: Associations With Cellular Lineage and Phenotype.
    J Crohns Colitis. 2017 Jul 17. doi: 10.1093.
    PubMed     Text format    


  205. FERRANTE M, de Buck van Overstraeten A, Schils N, Moens A, et al
    Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy.
    J Crohns Colitis. 2017 Jul 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  206. HIBI T, Panaccione R, Katafuchi M, Yokoyama K, et al
    The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management.
    J Crohns Colitis. 2017 Jul 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  207. PLANELL N, Masamunt MC, Leal RF, Rodriguez L, et al
    Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis.
    J Crohns Colitis. 2017 Jul 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  208. DURICOVA D, Leroyer A, Savoye G, Sarter H, et al
    Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study.
    J Crohns Colitis. 2017 Jul 7. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2017
  209. ESTEVINHO MM, Afonso J, Rosa I, Lago P, et al
    A Systematic Review and Meta-Analysis of 6-Thioguanine Nucleotide Levels and Clinical Remission in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Jun 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  210. ABREU C, Afonso J, Dias CC, Ruas R, et al
    Serial Tuberculosis screening in inflammatory bowel disease patients under anti-TNFalpha therapy.
    J Crohns Colitis. 2017 Jun 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  211. LEDDER O, Assa A, Levine A, Escher JC, et al
    Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN.
    J Crohns Colitis. 2017 Jun 9. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  212. BURISCH J, Vegh Z, Katsanos KH, Christodoulou DK, et al
    Occurrence of anaemia in the first year of inflammatory bowel disease in a European population-based inception cohort - An ECCO-EpiCom study.
    J Crohns Colitis. 2017 May 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  213. ANIWAN S, Loftus EV Jr
    Bringing the Mucosa to Heal with Vedolizumab in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 May 27. doi: 10.1093.
    PubMed     Text format    


  214. STREMMEL W, Staffer S, Schneider MJ, Gan-Schreier H, et al
    Genetic mouse models with intestinal-specific tight junction deletion resemble an ulcerative colitis phenotype.
    J Crohns Colitis. 2017 May 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  215. GASPAR R, Liberal R, Macedo G
    Mucosal healing in ulcerative colitis patients treated with vedolizumab: patient-, dose- or duration-dependant?
    J Crohns Colitis. 2017 May 22. doi: 10.1093.
    PubMed     Text format    


  216. CARBONNEL F, Boutron MC
    Incidence, phenotype and mortality of inflammatory bowel disease twenty years after.
    J Crohns Colitis. 2017 May 19. doi: 10.1093.
    PubMed     Text format    


  217. COX SR, Prince AC, Myers CE, Irving PM, et al
    Fermentable carbohydrates (FODMAPs) exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial.
    J Crohns Colitis. 2017 May 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  218. KAROLEWSKA-BOCHENEK K, Dziekiewicz M, Banaszkiewicz A
    Budesonide MMX in pediatric patients with ulcerative colitis.
    J Crohns Colitis. 2017 May 15. doi: 10.1093.
    PubMed     Text format    


  219. PARAMSOTHY S, Paramsothy R, Rubin DT, Kamm MA, et al
    Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2017 May 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  220. NIKOLAUS S, Schreiber S, Siegmund B, Bokemeyer B, et al
    Patient education in a 14 month randomized trial fails to improve adherence in ulcerative colitis: Influence of demographic and clinical parameters on non-adherence.
    J Crohns Colitis. 2017 May 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  221. BURISCH J, Ungaro R, Vind I, Prosberg MV, et al
    Proximal disease extension in patients with limited ulcerative colitis: a Danish population-based inception cohort.
    J Crohns Colitis. 2017 May 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  222. HORJUS TALABUR HORJE CS
    AlfaEbeta7 integrin expression on T cells in Ulcerative Colitis.
    J Crohns Colitis. 2017 May 9. doi: 10.1093.
    PubMed     Text format    


  223. MACMANUS CF, Collins CB, Nguyen TT, Alfano RW, et al
    VEN-120, a recombinant human lactoferrin, promotes a regulatory T cell (Treg) phenotype and drives resolution of inflammation in distinct murine models of inflammatory bowel disease.
    J Crohns Colitis. 2017 May 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  224. KOTZE PG, Yamamoto T
    Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: Does Smoke Always Mean Fire?
    J Crohns Colitis. 2017;11:643.
    PubMed     Text format    


  225. LAMB CA, Mansfield JC, Tew GW, Gibbons D, et al
    alphaEbeta7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis.
    J Crohns Colitis. 2017;11:610-620.
    PubMed     Text format     Abstract available


  226. CHU TPC, Moran GW, Card TR
    The Pattern of Underlying Cause of Death in Patients with Inflammatory Bowel Disease in England: A Record Linkage Study.
    J Crohns Colitis. 2017;11:578-585.
    PubMed     Text format     Abstract available


  227. LIM KJ, Lee SJ, Kim S, Lee SY, et al
    Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:593-602.
    PubMed     Text format     Abstract available


  228. LIGHTNER AL, Loftus EV
    Response to 'Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: Does Smoke Always Mean Fire?'
    J Crohns Colitis. 2017;11:644-645.
    PubMed     Text format    


  229. MELESSE DY, Lix LM, Nugent Z, Targownik LE, et al
    Estimates of Disease Course in Inflammatory Bowel Disease Using Administrative Data: A Population-level Study.
    J Crohns Colitis. 2017;11:562-570.
    PubMed     Text format     Abstract available


  230. KARREMAN MC, Luime JJ, Hazes JMW, Weel AEAM, et al
    The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2017;11:631-642.
    PubMed     Text format     Abstract available


  231. EBERHARDSON M, Karlen P, Linton L, Jones P, et al
    Randomised, Double-blind, Placebo-controlled Trial of CCR9-targeted Leukapheresis Treatment of Ulcerative Colitis Patients.
    J Crohns Colitis. 2017;11:534-542.
    PubMed     Text format     Abstract available


  232. DAPERNO M, Comberlato M, Bossa F, Armuzzi A, et al
    Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists.
    J Crohns Colitis. 2017;11:556-561.
    PubMed     Text format     Abstract available


  233. BEQUET E, Sarter H, Fumery M, Vasseur F, et al
    Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011].
    J Crohns Colitis. 2017;11:519-526.
    PubMed     Text format     Abstract available


  234. HOVDE O, Hoivik ML, Henriksen M, Solberg IC, et al
    Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study.
    J Crohns Colitis. 2017;11:571-577.
    PubMed     Text format     Abstract available


  235. TURNER D, Yerushalmi B, Kori M, Broide E, et al
    Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.
    J Crohns Colitis. 2017;11:527-533.
    PubMed     Text format     Abstract available


  236. MARAFINI I, Monteleone I, Dinallo V, Di Fusco D, et al
    CCL20 Is Negatively Regulated by TGF-beta1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide.
    J Crohns Colitis. 2017;11:603-609.
    PubMed     Text format     Abstract available


  237. ZITTAN E, Kabakchiev B, Kelly OB, Milgrom R, et al
    Development of the Harvey-Bradshaw Index-pro (HBI-PRO) Score to Assess Endoscopic Disease Activity in Crohn's Disease.
    J Crohns Colitis. 2017;11:543-548.
    PubMed     Text format     Abstract available


  238. DAVIDOV Y, Ungar B, Bar-Yoseph H, Carter D, et al
    Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease.
    J Crohns Colitis. 2017;11:549-555.
    PubMed     Text format     Abstract available


  239. EL MOUZAN M, Wang F, Al Mofarreh M, Menon R, et al
    Fungal Microbiota Profile in Newly Diagnosed Treatment-naive Children with Crohn's Disease.
    J Crohns Colitis. 2017;11:586-592.
    PubMed     Text format     Abstract available


    April 2017
  240. HARKIN G, Keogh A, Slattery E
    The Effect of Biosimilars (Inflectra(R),) in the management of Acute Severe Ulcerative Colitis.
    J Crohns Colitis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format    


  241. GWELA A, Siddhanathi P, Chapman RW, Travis S, et al
    Th1 and Innate Lymphoid Cells accumulate in Primary Sclerosing Cholangitis-associated Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Apr 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  242. GUIRGIS M, Wendt E, Wang LM, Walsh A, et al
    Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis.
    J Crohns Colitis. 2017;11:460-467.
    PubMed     Text format     Abstract available


  243. REINISCH W, Colombel JF, D'Haens G, Sandborn WJ, et al
    Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.
    J Crohns Colitis. 2017;11:425-434.
    PubMed     Text format     Abstract available


  244. DIAS CC, Rodrigues PP, Coelho R, Santos PM, et al
    Development and Validation of Risk Matrices for Crohn's Disease Outcomes in Patients Who Underwent Early Therapeutic Interventions.
    J Crohns Colitis. 2017;11:445-453.
    PubMed     Text format     Abstract available


  245. SCHOLMERICH J, Fellermann K, Seibold FW, Rogler G, et al
    A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease.
    J Crohns Colitis. 2017;11:390-399.
    PubMed     Text format     Abstract available


  246. ARSONIADIS EG, Ho YY, Melton GB, Madoff RD, et al
    African Americans and Short-Term Outcomes after Surgery for Crohn's Disease: An ACS-NSQIP Analysis.
    J Crohns Colitis. 2017;11:468-473.
    PubMed     Text format     Abstract available


  247. ALEXAKIS C, Gordon K, Mellor R, Chong H, et al
    Ano-genital Granulomatosis and Crohn's Disease: A Case Series of Males Presenting with Genital Lymphoedema.
    J Crohns Colitis. 2017;11:454-459.
    PubMed     Text format     Abstract available


  248. MAGRO F, Lopes S, Coelho R, Cotter J, et al
    Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis-the ACERTIVE study.
    J Crohns Colitis. 2017;11:435-444.
    PubMed     Text format     Abstract available


  249. MIKOCKA-WALUS A, Hughes PA, Bampton P, Gordon A, et al
    Fluoxetine for Maintenance of Remission and to Improve Quality of Life in Patients with Crohn's Disease: a Pilot Randomized Placebo-Controlled Trial.
    J Crohns Colitis. 2017;11:509-514.
    PubMed     Text format     Abstract available


  250. DING YP, Ladeiro Y, Morilla I, Bouhnik Y, et al
    Integrative Network-based Analysis of Colonic Detoxification Gene Expression in Ulcerative Colitis According to Smoking Status.
    J Crohns Colitis. 2017;11:474-484.
    PubMed     Text format     Abstract available


  251. LOFTUS EV JR, Colombel JF, Feagan BG, Vermeire S, et al
    Long-term Efficacy of Vedolizumab for Ulcerative Colitis.
    J Crohns Colitis. 2017;11:400-411.
    PubMed     Text format     Abstract available


  252. VERMEIRE S, Loftus EV Jr, Colombel JF, Feagan BG, et al
    Long-term Efficacy of Vedolizumab for Crohn's Disease.
    J Crohns Colitis. 2017;11:412-424.
    PubMed     Text format     Abstract available


  253. SMIDS C, Horjus Talabur Horje CS, van Wijk F, van Lochem EG, et al
    The Complexity of alpha E beta 7 Blockade in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2017;11:500-508.
    PubMed     Text format     Abstract available


    March 2017
  254. WISNIEWSKI A, Flejou JF, Siproudhis L, Abramowitz L, et al
    Anal Neoplasia in Inflammatory Bowel Disease: Classification Proposal, Epidemiology, Carcinogenesis, and Risk Management Perspectives.
    J Crohns Colitis. 2017 Mar 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  255. NOMAN M, Ferrante M, Bisschops R, De Hertogh G, et al
    Vedolizumab induces long term mucosal healing in patients with Crohn's disease and ulcerative colitis.
    J Crohns Colitis. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  256. LEVINE A, Yerushalmi B, Kori M, Broide E, et al
    Mesalamine enemas for induction of remission in oral mesalamine refractory pediatric ulcerative colitis: a prospective cohort study.
    J Crohns Colitis. 2017 Mar 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  257. COTON C, Maggiori L, Mege D, Naudot C, et al
    Ileal pouch-anal anastomosis for dysplasia or cancer complicating inflammatory bowel disease: Is total mesorectal excision always mandatory? an analysis of 36 consecutive patients.
    J Crohns Colitis. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  258. REBOREDO MM, Pinheiro BV, Chebli JM
    Physical exercise programs in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format    


  259. CANTORO L, Di Sabatino A, Papi C, Margagnoni G, et al
    The time course of diagnostic delay in inflammatory bowel disease over the last sixty years: an Italian multicentre study.
    J Crohns Colitis. 2017 Mar 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  260. JUNG YS, Han M, Kim WH, Park S, et al
    Cancer risk in the Early Stages of Inflammatory Bowel Disease in Korean patients: A Nationwide Population-based Study.
    J Crohns Colitis. 2017 Mar 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  261. MOHAMMED K, Shaik NA, Al-Abbasi FA
    Novel de novo mutations of the interleukin-10 receptor gene lead to infantile onset inflammatory bowel disease: A Correction.
    J Crohns Colitis. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format    


  262. WISNIEWSKI A, Flejou JF, Siproudhis L, Abramowitz L, et al
    Anal neoplasia in Inflammatory Bowel Disease: Classification proposal, epidemiology, carcinogenesis and risk management perspectives.
    J Crohns Colitis. 2017 Mar 10. doi: 10.1093.
    PubMed     Text format     Abstract available



  263. Corrigendum: The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Mar 9. doi: 10.1093.
    PubMed     Text format    



  264. Erratum: Use of digital technology to boost patient recruitment in inflammatory bowel disease clinical trials.
    J Crohns Colitis. 2017 Mar 9. doi: 10.1093.
    PubMed     Text format    


  265. RUBIN DT, Cohen RD, Sandborn WJ, Lichtenstein GR, et al
    Budesonide Multi-Matrix Is Efficacious for Mesalamine-Refractory, Mild to Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Trial.
    J Crohns Colitis. 2017 Mar 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  266. BOJIC D, Bodger K, Travis S
    Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data.
    J Crohns Colitis. 2017;11.
    PubMed     Text format     Abstract available


  267. VILLANACCI V, Baert F, Cornillie F, De Hertogh G, et al
    Challenges Faced by Cross-sectional Imaging and Histological Endpoints in Clinical Trials.
    J Crohns Colitis. 2017;11.
    PubMed     Text format     Abstract available


  268. FIORINO G, Morin M, Bonovas S, Bonifacio C, et al
    Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome.
    J Crohns Colitis. 2017;11:274-280.
    PubMed     Text format     Abstract available


  269. BUER LC, Moum BA, Cvancarova M, Warren DJ, et al
    Switching from Remicade(R) to Remsima(R) is well Tolerated and Feasible: A Prospective, Open-label Study.
    J Crohns Colitis. 2017;11:297-304.
    PubMed     Text format     Abstract available


  270. MOURAD FH, Barada KA, Saade NE
    Impairment of Small Intestinal Function in Ulcerative Colitis: Role of Enteric Innervation.
    J Crohns Colitis. 2017;11:369-377.
    PubMed     Text format     Abstract available


  271. DIBLEY L, Bager P, Czuber-Dochan W, Farrell D, et al
    Identification of Research Priorities for Inflammatory Bowel Disease Nursing in Europe: a Nurses-European Crohn's and Colitis Organisation Delphi Survey.
    J Crohns Colitis. 2017;11:353-359.
    PubMed     Text format     Abstract available


  272. SEVERS M, Mangen MJ, van der Valk ME, Fidder HH, et al
    Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:342-352.
    PubMed     Text format     Abstract available


  273. CESARINI M, Collins GS, Ronnblom A, Santos A, et al
    Predicting the Individual Risk of Acute Severe Colitis at Diagnosis.
    J Crohns Colitis. 2017;11:335-341.
    PubMed     Text format     Abstract available


  274. KOLHO KL, Pessia A, Jaakkola T, de Vos WM, et al
    Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:321-334.
    PubMed     Text format     Abstract available


  275. DECOCK A, Van Assche G, Vermeire S, Wuyts W, et al
    Sarcoidosis-Like Lesions: Another Paradoxical Reaction to Anti-TNF Therapy?
    J Crohns Colitis. 2017;11:378-383.
    PubMed     Text format     Abstract available


  276. COLLINS M, Sarter H, Gower-Rousseau C, Koriche D, et al
    Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence.
    J Crohns Colitis. 2017;11:281-288.
    PubMed     Text format     Abstract available


  277. SEVERS M, Oldenburg B, van Bodegraven AA, Siersema PD, et al
    The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:289-296.
    PubMed     Text format     Abstract available


  278. JAUREGUI-AMEZAGA A, Geerits A, Das Y, Lemmens B, et al
    A Simplified Geboes Score for Ulcerative Colitis.
    J Crohns Colitis. 2017;11:305-313.
    PubMed     Text format     Abstract available


  279. KEANE TJ, Dziki J, Sobieski E, Smoulder A, et al
    Restoring Mucosal Barrier Function and Modifying Macrophage Phenotype with an Extracellular Matrix Hydrogel: Potential Therapy for Ulcerative Colitis.
    J Crohns Colitis. 2017;11:360-368.
    PubMed     Text format     Abstract available


    February 2017
  280. LEE HS, Oh H, Baek J, Jung S, et al
    X chromosome-wide association study identifies a susceptibility locus for inflammatory bowel disease in Koreans.
    J Crohns Colitis. 2017 Feb 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  281. UCHIYAMA K, Takagi T, Kashiwagi S, Toyokawa Y, et al
    Assessment of endoscopic mucosal healing of ulcerative colitis using linked colour imaging, a novel endoscopic enhancement system.
    J Crohns Colitis. 2017 Feb 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  282. DANESE S, Bonovas S, Peyrin-Biroulet L
    Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile.
    J Crohns Colitis. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format    


  283. UZZAN M, Kirchgesner J, Oubaya N, Amiot A, et al
    Risk of rectal neoplasia after colectomy and ileorectal anastomosis for ulcerative colitis.
    J Crohns Colitis. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  284. ROSARIO M, French JL, Dirks NL, Sankoh S, et al
    Exposure-Efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
    J Crohns Colitis. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  285. RUIZ DE MORALES JG, Munoz F, Hernando M
    Successful treatment of Common Variable Immunodeficiency-associated inflammatory bowel disease with Ustekinumab.
    J Crohns Colitis. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format    


  286. TAXONERA C, Ponferrada A, Bermejo F, Riestra S, et al
    Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  287. LYKOURAS D, Karkoulias K, Triantos C
    Physical Exercise in Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Feb 10. doi: 10.1093.
    PubMed     Text format    


  288. MAGRO F, Gionchetti P, Eliakim R, Ardizzone S, et al
    Third European Evidence-Based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders.
    J Crohns Colitis. 2017 Feb 2. doi: 10.1093.
    PubMed     Text format    


  289. VAN RHEENEN PF, Aloi M, Biron IA, Carlsen K, et al
    European Crohn's and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Feb 2. doi: 10.1093.
    PubMed     Text format    


  290. DE VRIES L, Wildenberg M, de Jonge W, D'Haens G, et al
    The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017 Feb 2. doi: 10.1093.
    PubMed     Text format    


  291. ONIDI FM, Mocci G, Cabras F
    N814 Improvement in the treatment and management of patients affected by inflammatory bowel disease: hepatitis B and vaccination status.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  292. SHAH SC, Khalili H, Gower-Rousseau C, Olen O, et al
    P734 The sex ratio of inflammatory bowel disease varies according to age at onset: results from a worldwide survey.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  293. SILVA RP, Bissoli GC, Farinelli E, Sibia CF, et al
    N811 Infliximab versus adalimumab: clinical and endoscopy response in ulcerative colitis patients. A prospective study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  294. MANCENIDO MARCOS N, Pajares Villarroya R, Salinas Moreno S, Arribas Lomicronpez MR, et al
    P697 Association of inflammatory bowel disease and celiac disease. Experience in a hospital of the autonomous community of Madrid (Spain).
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  295. HIRANO A, Umeno J, Shibata H, Kitazono T, et al
    P784 A comparison study of the mucosa-associated microbiota between inflamed and non-inflamed sites in ulcerative colitis patients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  296. PONCE-ALONSO M, Garcia-Fernandez S, Aguilera L, Rodriguez-de-Santiago E, et al
    P782 A new compatibility test for donor selection for faecal microbiota transplantation in ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  297. BASTON I, Sueiro R, Uribarri L, Ferreiro R, et al
    P785 Association of Bacteroidetes with endoscopic activity in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  298. RICANEK P, Rahul K, Ber Y, Vatn S, et al
    P788 Microbiota related disease activity and distribution in subgroups of inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  299. RIVERA SEQUEIROS A, Gil Garcia E, Chillomicronn Martinez R
    N800 Statistical comparison of predictors of quality of life in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  300. SLADEK M, Vultaggio A, Ghione S, Nencini F, et al
    P661 Comparable clinical efficacy, safety and immunogenicity of infliximab biosimilar (CT-P13) after transition from reference infliximab (Remicade(R)) in children with established inflammatory bowel disease: a multi-centre prospective observational s
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  301. HELLSTROM PM, Stalhammar J, Beydogan H, Huetson P, et al
    P735 Indirect burden of patients with moderate inflammatory bowel disease in Uppsala County Council, Sweden: a retrospective study using real-world data.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  302. ISHIKAWA D, Takahashi M, Haga K, Shibuya T, et al
    P766 Combination therapy of fresh fecal microbial transplantation and antibiotics for ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  303. DING NS, Yazdanian B, Bettenworth D, Cleynen I, et al
    P738 Assessing aCCess to investigations in IBD (ACCID) - results from an international inflammatory bowel disease survey.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  304. FONSECA CAMARILLO G, Iturriaga Goyon E, Yamamoto Furusho JK
    P765 Transcriptome of intestinal epithelial barrier genes in the colonic mucosa from patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  305. BORREN N, Tan W, Andrews E, Khalili H, et al
    P704 The impact of travel distance on disease outcomes in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  306. SIBIA CF, Silva RP, Ariede JR, Severino FE, et al
    P760 microRNA expression profiling of inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  307. JELAKOVIC M, Brinar M, Turk N, Prijic R, et al
    P747 Extracolonic and colonic cancer risk in patients with ulcerative colitis and primary sclerosing cholangitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  308. FRAGAKI M, Bachlitzanaki M, Karmiris K, Theodoropoulou A, et al
    P709 inflammatory bowel disease and colorectal cancer: analysis of a single center retrospective chart review.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  309. CROWLEY E, Elkadri A, Warner N, Zhang S, et al
    P754 X-linked inhibitor of apoptosis protein genetic variants in paediatric-onset inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  310. FONSECA CAMARILLO G, Iturriaga Goyon E, Yamamoto Furusho JK
    P762 Gene expression profiling of immune adaptive response in the colonic mucosa from patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  311. DIBLEY L, Williams E, Young P, Ironside P, et al
    N798 Kinship stigma in community-dwelling people with inflammatory bowel disease: family acknowledgement matters.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  312. RASMUSSEN M, Brynskov J, Ainsworth MA, Buhl S, et al
    P584 A role for therapeutic drug-monitoring during infliximab induction treatment in inflammatory bowel disease?
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  313. GOMPERTZ M, Alfaro I, Ricart E, Lomicronpez A, et al
    P679 Infliximab biosimilar CT-P13 in inflammatory bowel disease patients that require intensification treatment.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  314. FIORINO G, Ruiz-Aguello MB, Maguregui A, Nagore D, et al
    P633 Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  315. GARCIA ORTIZ JM, Saenz Gallo M, Trigo Salado C, De La Cruz Ramirez MD, et al
    P634 Long term risk of relapse after anti-TNF discontinuation based on mucosal healing in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  316. SANDBORN W, Sakuraba A, Wang A, Macaulay D, et al
    P676 Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  317. MOLNAR T, Farkas K, Rutka M, Ferenci T, et al
    P675 Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohn's disease and ulcerative colitis - 54 week data.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  318. CHAO CY, Lemieux C, Afif W, Bitton A, et al
    P677 Impact of patient reported outcomes, coping strategies and psychosocial factors on medication adherence in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  319. RODRIGUEZ GLEZ GE, Diaz Hernandez L, Morales Barrios JA, Vela Gonzalez M, et al
    P629 Efficacy, safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice: results of one year.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  320. DE VILLE DE GOYET L, Moreels T, Denis MA, De Vroey B, et al
    P732 Clinical characteristics of inflammatory bowel disease in Belgian immigrants from Moroccan and Caucasian origin.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  321. ROSEIRA J, Tavares de Sousa H, Marreiros A, Estevens D, et al
    P723 SexIDI study - sexual satisfaction in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  322. MYRELID P, Landerholm K, Nordenvall C, Pinkney TD, et al
    P724 Appendectomy is not a treatment option for ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  323. DERWA Y, Gracie DJ, Williams CJ, Sood R, et al
    P655 A study to determine factors affecting clinical decision making in outpatients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  324. RIVIERE P, Laharie D, Zerbib F, Poullenot F, et al
    P680 Quality of sex life in patients with inflammatory bowel disease: the gastroenterologists' perspective.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  325. MCGOWAN M, Kokkorou M, Rebull M, Koh Y, et al
    P587 Fermentation capacity of gut microbiota in patients with inflammatory bowel disease compared to healthy controls.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  326. AKSAN A, Isik H, Radeke HH, Dignass A, et al
    P620 Network meta-analysis of efficacy and safety of different intravenous iron compounds for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  327. HUGUET M, Pereira B, Goutte M, Goutorbe F, et al
    P628 Anti-TNF therapy in refractory pouchitis and Crohn's disease-like complications of the pouch after ileal pouch-anal anastomosis following colectomy for ulcerative colitis: a systematic review and meta-analysis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  328. PENA-SANCHEZ JN, Lix LM, Teare GF, Li W, et al
    P725 The impact of an integrated model of care for patients with inflammatory bowel disease in Canada.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  329. EL-MATARY W, Deora V
    P651 Barriers to clinical research in children with inflammatory bowel disease: the patients' perspective.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  330. SUTTON R, Wierstra K, Ambrosio L, Dieleman L, et al
    P552 An online educational portal improves concerns of inflammatory bowel disease patients regarding pregnancy and medication.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  331. SCHREIBER S, Dignass A, Peyrin-Biroulet L, Hather G, et al
    P466 Real world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  332. KIM KO, Jang BI, Koo EJ, Kang MK, et al
    P657 The predictors and clinical outcomes of follow up loss of clinics in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  333. KOO JS, Kim DJ, Lee DW, Jeen YJ, et al
    P604 Usefulness of stool hemoglobin and fecal calprotectin for detecting of mild to moderate ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  334. FIORINO G, Ametzazurra A, Nagore D, Hernandez AM, et al
    P605 Rapid detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the reference biologic or the biosimilar CT-P13: performance comparison with ELISA.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  335. TANAKA T, Goishi H, Kajihara T, Akagi M, et al
    P518 Remission induction in corticosteroid naive children and adolescents with ulcerative colitis by adsorptive leucocytapheresis as monotherapy or in combination with low dose prednisolone after failure of first-line medications.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  336. YLISAUKKO-OJA T, Eberl A, Aaltonen J, Nuutinen H, et al
    P515 Evaluation of treatment persistence of vedolizumab among Finnish inflammatory bowel disease patients in real-life clinical practice (FINVEDO).
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  337. RASMUSSEN M, Brynskov J, Ainsworth MA, Buhl S, et al
    P643 Therapeutic thresholds for infliximab trough levels during maintenance treatment in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  338. YAMAMOTO T, Tanaka T, Yokoyama T, Shimoyama T, et al
    P540 Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  339. KANG B, Lee K, Choe YH
    P542 Long-term outcomes after switching from originator infliximab to biosimilar in paediatric-onset inflammatory bowel disease patients: a single centre prospective observational study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  340. LITTLE R, Taylor K, Friedman A, Headon B, et al
    P609 A treat-to-target approach via a virtual clinic amongst inflammatory bowel disease patients with secondary loss of response to anti-TNF therapy improves clinical outcomes.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  341. NORTON C, Czuber-Dochan W, Artom M, Sweeney L, et al
    P555 Systematic review of interventions for chronic abdominal pain management in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  342. SAIBENI S, Bezzio C, Armuzzi A, Bossa F, et al
    P652 Unmet needs of physicians managing inflammatory bowel disease. A Survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD).
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  343. GREWAL CS, Sood A, Mehta V, Kaur D, et al
    P596 FMT in patients with steroid dependant ulcerative colitis a single centre observational study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  344. NARULA N, Borges L, Steinhart AH, Colombel JF, et al
    P415 Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  345. YOKOYAMA K, Kawagishi K, Kobayashi K, Koizumi W, et al
    P570 Current status of the effectiveness of infliximab in patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  346. MANOSA M, Corrales G, Olivares D, Vicuna M, et al
    P480 Characteristics of drug-induced lupus 2 degrees to anti-TNF agents in inflammatory bowel disease patients and evolution after switch to a second anti-TNF.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  347. GULATI S, Emmanuel A, Burt M, Hayee B, et al
    P535 Outcomes of endoscopic resections of large non-polypoid lesions inflammatory bowel disease: a single United Kingdom centre experience.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  348. WALJEE A, Liu B, Sauder K, Zhu J, et al
    P361 Machine learning models at week 6 of vedolizumab therapy for ulcerative colitis can predict week 52 corticosteroid free endoscopic remission.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  349. PROTIC M, Seibold F, Manser C, Frei P, et al
    P569 Sequential rescue treatments in steroid refractory ulcerative colitis: two-year follow-up.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  350. KOLAR M, Duricova D, Bortlik M, Hruba V, et al
    P532 Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients - one-year clinical follow-up.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  351. SPIZZO P
    P556 Female Crohn's disease patients and ulcerative colitis patients on biologic therapy are most disabled.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  352. BRYANT R, Costello S, Schoeman S, Sathananthan D, et al
    P577 "Treat to target" recommendations in ulcerative colitis in practice: clinician perceptions and potential barriers.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  353. YE L, Liu J, Lin Z, Cao Q, et al
    P568 Does infliximab therapy increase incidence of tuberculosis in patients with inflammatory bowel disease in an endemic area: a nationwide study from China.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  354. LOBATON T, Canete F, Teniente A, Cabre E, et al
    P562 Real-life infliximab trough levels among inflammatory bowel disease patients on maintenance therapy: should we redefine therapeutic range based on inflammatory load?
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  355. AMETZAZURRA A, Rivera N, Hernandez AM, Arreba MP, et al
    P503 Rapid point-of-care monitoring of anti-infliximab antibodies in patients with inflammatory bowel disease treated with the reference infliximab or CT-P13 in routine clinical practice.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  356. YADAV A, Forry M, O'Toole A, Patchett S, et al
    P520 Perspective and self-efficacy of adolescents with inflammatory bowel disease post transition to adult care.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  357. BERNARDO S, Fernandes S, Goncalves AR, Baldaia C, et al
    P453 Efficacy of therapeutic drug monitoring of anti-TNF therapy in the control of patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  358. ESTEVEZ-GIL M, De Castro ML, Hernandez V, Pineda JR, et al
    P455 Clinical features of tuberculosis infection in inflammatory bowel disease patients on anti-TNF therapy.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  359. CARMAN N, Huynh H, Walsh CM, Ricciuto A, et al
    P450 Reliability assessment of endoscopic scoring tools using central video review of colonoscopies in paediatric patients with ulcerative colitis: data from the Canadian Children IBD Network.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  360. PITUCH-ZDANOWSKA A, Stawicka A, Jarocka-Cyrta E, Banaszkiewicz A, et al
    P346 Dietary practices and beliefs among parents of children with inflammatory bowel disease: preliminary results.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  361. HAZEL K, Forry M, Patchett S, O'Toole A, et al
    P371 Healthcare maintenance in inflammatory bowel disease patients: need for a top down approach.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  362. SAIBENI S, Bezzio C, Armuzzi A, Bossa F, et al
    P574 Limitations and difficulties in using anti-TNF-alpha agents in inflammatory bowel disease. A survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD).
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  363. HEIDA A, Knol M, Muller Kobold A, Dijkstra G, et al
    P374 Home or hospital-based analysis of stool calprotectin: assessing two methods for monitoring inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  364. SOUSA P, Martins D, Pinho J, Cancela E, et al
    P284 Ulcerative colitis - presentation during pregnancy or puerperium.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  365. AL KHOURY A, Chao CY, Aruljothy A, Wyse J, et al
    P495 Intensified infliximab rescue therapy for acute severe ulcerative colitis does not improve long term colectomy-free survival.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  366. BALABAN DV, Popp A, Robu G, Bucurica S, et al
    P323 Fatty liver assessment in inflammatory bowel disease patients using controlled attenuation parameter.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  367. MELLOTTE G, McShane C, O'Connell J, Mc Kiernan S, et al
    P491 Comparison of the durability of response to subcutaneous anti-TNF therapy between ulcerative colitis and Crohn's disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  368. FUH F, Tew W, Keir M, Looney C, et al
    P431 Colonic Treg levels are reduced in patients with ulcerative colitis achieving clinical remission, but are not differentially affected by etrolizumab dose.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  369. PUGLIESE D, Armuzzi A, Panici Tonucci T, Tolusso B, et al
    P440 Therapeutic drug monitoring of infliximab for the management of loss of response in inflammatory bowel disease: an observational multicenter study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  370. SIECZKOWSKA-GOLUB J, Jarzebicka D, Borys-Iwanicka A, Korlatowicz-Bilar A, et al
    P504 Differences between paediatric and adult inflammatory bowel disease presentation - analysis based on the data from multicenter, prospective cohort observational study assessing safety of anti-TNF therapy - Satimos study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  371. TRAVIS S, Feagan B, Peyrin-Biroulet L, Panaccione R, et al
    P329 Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  372. ORLANDINI B, Dragoni G, Bagnoli S, Deiana S, et al
    P407 Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naive patients with moderate to severe ulcerative colitis: experience from a tertiary referral centre.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  373. GHOSH S, Peyrin-Biroulet L, Sensky T, Casellas F, et al
    P359 Correlation between physician and patient disease assessments in ulcerative colitis: baseline data from the ICONIC study of 1816 patients in 33 countries.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  374. MARSHALL JK, Marrache AM, Ewara E
    P383 Increasing treatment time on REMICADE(R) (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in Canada.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  375. PEREZ-PAMPIN E, Ferreiro R, Lorenzo A, Mera A, et al
    P285 Usefulness of a multidisciplinary approach combining both rheumatology and gastroenterology for the assessment and treatment of inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  376. MULCAHY H, Wynne B, McHugh L, Rowan C, et al
    P370 A randomised controlled trial of acceptance and commitment therapy for the treatment of stress in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  377. ZAMBORSKY T, Berakova K, Kadleckova B, Podmanicky D, et al
    P339 MadCAM1 expression in intestinal lamina propria endothelium varies among inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  378. PARRA RS, Feitosa MR, Feres O, Rocha JJ, et al
    P424 Association between infliximab trough levels, clinical remission, mucosal healing and quality of life in patients with inflammatory bowel disease on maintenance therapy.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  379. MANTAKA A, Renieri V, Koutroubakis I
    P340 Prevalence and long-term effect of antiplatelet use in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  380. KEETARUT K, Bloom S, Qu X, Grimble G, et al
    P376 Assessment of nutritional status and food related experience of adult inflammatory bowel disease inpatients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  381. OGASHIWA T, Nishio M, Otake H, Inoue E, et al
    P337 Efficacy of intravenous cyclosporine in fulminant steroid-refractory ulcerative colitis with massive bleeding: a retrospective, observational study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  382. MORTIER K, Arnott I, Russell RK
    P333 Changing patterns of biological therapy use with the introduction of biosimilars in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  383. GUBATAN JM, Mitsuhashi S, Longhi MS, Zenlea T, et al
    P344 Vitamin D-Induced alterations in Cytokine levels lower the risk of clinical relapse in ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  384. YANG HR, Cho JM
    P237 Hair mineral and trace element contents as reliable markers of nutritional status compared to serum levels in children with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  385. KIM M
    P399 Adverse events associated with azathioprine treatment in Korean pediatric inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  386. LEVINE A, Yerushalmi B, Kori M, Broide E, et al
    P409 Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: a prospective cohort study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  387. COHEN S, Martinez-Vinson C, Aloi M, Turner D, et al
    P302 Cytomegalovirus infection in pediatric acute severe ulcerative colitis - a multicenter case-controlled study from the Pediatric IBD Porto group of ESPGHAN.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  388. COHEN I, Benyamini Y, Tulchinsky H, Dotan I, et al
    P300 Illness perceptions and coping with health-related quality of life in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  389. MEGLICKA M, Szczepanski M, Bierla J, Dadalski M, et al
    P265 Comparison of two faecal calprotectin assays in monitoring children with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  390. PITTET V, Maillard MH, Rogler G, Michetti P, et al
    P298 Comparison between clinical and patient-reported symptoms among Crohn's disease and ulcerative colitis patients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  391. WILLIET N, Nancey S, Boureille A, Altwegg R, et al
    P310 Development of a new clinico-biological score associated with disease activity in patients with inflammatory bowel disease treated with thiopurine.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  392. GONZALEZ-LOPEZ J, Giraldez-Montero JM, Ferreiro R, Lorenzo A, et al
    P280 Therapeutic drug monitoring of infliximab and adalimumab for detection of patients at risk of loss of response in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  393. MAJOROVA E, Susterova I, Kolarcik P, Fandakova I, et al
    P247 Fungal infections in children with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  394. LIMSRIVILAI J, Stidham RW, Govani S, Waljee A, et al
    P303 Gastrointestinal infectious agents detected by Biofire FilmArray GI PCR panel stool testing in active inflammatory bowel disease are common and associated with a more benign course of IBD.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  395. FERREIRA J, Thomas S, Tomer G
    P334 Medication adherence in diverse inner city pediatric patients with inflammatory bowel disease and comparison to physician perception of adherence.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  396. YI F
    P286 Evaluation of fecal S100A12 in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  397. BUDZYNSKA A, Nowakowska-Dulawa E, Gawron-Kiszka M, Spiewak J, et al
    P189 Serum neutrophil gelatinase-associated lipocalin correlates with Mayo Clinic score in ulcerative colitis but fails to predict activity in Crohn's disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  398. LORES T, Goess C, Hrycek C, Grafton R, et al
    P238 Mental health issues and healthcare utilisation in outpatients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  399. ADMYRE C, Zargari A, Atreya R, Knittel T, et al
    P080 IL-10 induction properties of the TLR-9 agonist cobitolimod - a candidate for treatment of active ulcerative colitis in late stage of clinical development.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  400. LEE SH, Seo H, Chang K, Song EM, et al
    P148 Fecal calprotectin as a noninvasive indicator for ulcerative colitis disease activity in the Korean cohort.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  401. SMIDS C, Horjus Talabur Horje C, Groenen M, van Koolwijk E, et al
    P313 Glycan antibodies and pANCA in newly diagnosed inflammatory bowel disease patients at presentation and during follow-up.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  402. PAUL S, Duru G, De Vries A, Marini JC, et al
    P226 Comparison of four different immunoassays for measuring golimumab and anti-golimumab antibody concentration in patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  403. HICKS L, Powles S, Swann J, Chong L, et al
    P182 Assessing the effect of ethnicity on urinary metabolic profiles in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  404. CHAPARRO M, Barreiro-de Acosta M, Echarri A, Almendros R, et al
    P186 Association between anti-TNF serum levels and mucosal healing in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  405. BOUTALEB A, Saoula H, Aissaoui M, Hamidouche D, et al
    P206 Celiac disease and inflammatory bowel disease, a rare association.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  406. BITTL M, Petersen F, Maaser C, Rath S, et al
    P171 Reliable assessment of ultrasound parameters during transabdominal ultrasonography in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  407. WEI SC, Shih IL, Lin BR, Yen RF, et al
    P199 PET/MR for evaluating subclinical inflammation of ulcerative colitis in remission.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  408. ZHANG W, Teng G, Wang H, Tian Y, et al
    P166 Decreased expression of elafin in peripheral blood and intestinal mucosa in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  409. ZAMBRANO PEREZ A, Shergill-Bonner R, Kiparissi F, Acton N, et al
    P219 Inflammatory bowel disease in children is a challenging diagnosis when overlaps with coeliac disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  410. OHTA Y, Taida T, Nakagawa T, Hamanaka S, et al
    P231 Backgrounds and D-dimer on admission are useful factors for predicting venous thromboembolic complications in hospitalized patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  411. UDUPA V, Baird A, Winter D
    P109 Profiling of receptor for advanced glycation end products expression in cases of primary sclerosing cholangitis with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  412. FONSECA CAMARILLO G, Furuzawa Carballeda J, Iturriaga Goyon E, Yamamoto Furusho JK, et al
    P042 Expression of IL-38 and their antagonists in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  413. LOMICRONPEZ-SERRANO A, Paredes JM, Polanco A, Garcia C, et al
    P224 Virtual chromoendoscopy with i-Scan as alternative to dye-spray chromoendoscopy for dysplasia detection in long-standing colonic inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  414. TEIXEIRA C, Martins C, Ribeiro S, Trabulo D, et al
    P137 Ulcerative colitis in the elderly - Different disease course?
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  415. ZARGARI A, Admyre C, Knittel T
    P106 Binding properties of human TLR-9 receptor to cobitolimod - a candidate for treatment of active ulcerative colitis in late stage of clinical development.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  416. CHAO K, Zhu X, Cao Q, Yang H, et al
    P096 Combined detection variants of NUDT15 could highly predict thiopurine-induced leukopenia in Chinese patients with inflammatory bowel disease: a multi-center analysis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  417. TAIDA T, Nakagawa T, Fujie M, Ohta Y, et al
    P159 Real-time endoscopic-guided measurement of rectal mucosal admittance: a novel and safety method for prediction of relapse in ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  418. ROTTOLI M, Vallicelli C, Bigonzi E, Di Simone M, et al
    DOP041 Prepouch ileitis after ileal pouch anal anastomosis for ulcerative colitis: patterns of presentation and risk factors for failure of treatment.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  419. CARMAN N, Huynh H, Mouzaki M, Crowley E, et al
    DOP072 Assessment of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) using central video review of colonoscopies in paediatric patients with ulcerative colitis: data from the Canadian Children IBD Network.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  420. ATREYA R, Kuhbacher T, Waldner MJ, Hirschmann S, et al
    DOP073 Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided ulcerative colitis patients with moderate-to-severe disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  421. BORREN N, Goel G, Lassen K, Devaney K, et al
    P023 Fatigue in quiescent inflammatory bowel disease is associated with low GM-CSF levels and metabolomic alterations.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  422. VANDE CASTEELE N, Jairath V, Levesque B, Feagan B, et al
    DOP033 Severely active ulcerative colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomes.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  423. GAGNIERE C, Bourrier A, Seksik P, Gornet JM, et al
    DOP011 Risk of opportunistic infection in healthcare personnel with inflammatory bowel disease: a case-control study of the GETAID.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  424. COSTELLO S, Waters O, Bryant R, Katsikeros R, et al
    OP036 Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  425. SPEKHORST L, Severs M, de Boer NK, Festen EA, et al
    DOP004 Ethnicity and country of birth are associated with phenotypic differences in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  426. DULAI P, Buckey J, Raffals L, Swoger J, et al
    OP021 Hyperbaric oxygen therapy is safe and effective for hospitalized ulcerative colitis patients suffering from moderate-severe flares: a multi-center, randomized, double-blind, sham-controlled trial.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  427. BURISCH J, Vind I, Prosberg M, Colombel JF, et al
    DOP003 Proximal disease extension in patients with limited ulcerative colitis: a Danish population-based inception cohort.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  428. BOTS S, Hoekman D, Benninga M, Ponsioen C, et al
    DOP017 Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  429. IQBAL T, Beggs A, Taniere P, Wallis Y, et al
    OP002 Epigenetic biomarkers to detect ulcerative colitis-associated neoplasia: results from phase I of the ENDCAP-C study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  430. SACLEUX SC, Charpentier C, Sarter H, Fumery M, et al
    DOP045 Post-operative complications in elderly-onset inflammatory bowel disease: a population-based study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  431. SANDBORN WJ, Cyrille M, Hansen MB, Feagan BG, et al
    OP034 Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  432. DE FRANCISCO R, Riestra S, Perez-Martinez I, Castano A, et al
    DOP012 Impact on clinical practice of Epstein-Barr virus infection in patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  433. SIGALL BONEH R, Levine A, Lomer M, Wierdsma N, et al
    DOP006 Research gaps in diet and nutrition in inflammatory bowel disease. A topical review by ECCO.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  434. DE JONG M, van der Meulen-de Jong A, Romberg-Camps M, Becx M, et al
    OP017 Telemedicine enables a safe shift from examination room based care to personalised care for inflammatory bowel disease: a pragmatic randomised multicenter trial with myIBDcoach.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  435. SANDBORN W, Feagan B, D'Haens G, Levesque B, et al
    OP014 Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extension.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  436. STALLMACH A, Bokemeyer B, Axler J, Curtis R, et al
    DOP026 Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  437. SELLGE G, Papoutsopoulou S, Verdier J, Trautwein C, et al
    DOP049 Inflammatory dyskinesis: defects of NF-kappaB dynamic behaviour as a new potential biomarker for personalized medicine in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  438. MOUTSIANAS L, De Lange K, Luo Y, Lee J, et al
    OP001 Whole genome sequencing and imputation in inflammatory bowel disease identifies 26 novel loci and offers therapeutically-relevant mechanistic insights.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  439. FARINELLI E, Pagnin AF, Silva RP, Sibia CF, et al
    N817 Epidemiological profile of Crohn's disease and ulcerative colitis in a Brazilian single centre.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  440. VINAYAGA-PAVAN M, Frampton M, Pontikos N, Levine A, et al
    P758 Elevation in ribosomal and cell cycle gene transcription in macroscopically normal colonic tissue from Icelandic patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  441. OLBJORN C, Cvancarova Smastuen M, Casen C, Nakstad B, et al
    P778 Microbial characterization of paediatric inflammatory bowel disease and stratification into disease severity groups.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  442. GORDILLO J, Torres P, Garcia-Garcia de Paredes A, Llaomicron J, et al
    P706 Caracterization of de novo inflammatory bowel disease (IBD) diagnosed in immigrants migrating from low to high prevalence areas of IBD: a case-control study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  443. BARROS J, Baima J, Renosto F, Sibia C, et al
    NO001 Clinical and psychological factors associated with Erectile Dysfunction in inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  444. SANROMAN ALVAREZ L, Figueira Alvarez M, De Castro Parga ML, Hernandez Ramirez V, et al
    N801 Patient opinion assessment of a comprehensive clinical tool to improve health-care in inflammatory bowel disease. The Implica-2 project.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  445. BRANCO JC, Cardoso M, Anapaz V, Lourenco L, et al
    P714 Vitamin D deficiency in inflammatory bowel disease: prevalence and relation to disease activity in a cohort of patients of a Mediterranean country.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  446. JOHNS K
    N810 Audit of patient satisfaction with telephone reviews for inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  447. SARID O, Slomin-Nevo V, Schwartz D, Friger M, et al
    P749 Impact of psycho-social variables on the activity of inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  448. LIM WC, Lin H
    P660 Prevalence and clinical course of cytomegalovirus colitis in Asian patients with acute exacerbation of ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  449. SILVA RP, Baima JP, Bissoli GC, Farinelli E, et al
    N816 Anti-TNF therapy improves the quality of life in patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  450. MORREALE GC, Calvaruso V, Sanfratello A, Cappello M, et al
    P658 The Inflammatory Bowel Disease Disability Index (IBD-DI) in ulcerative colitis is related to disease activity, need of immunosuppressive therapy and quality of life.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  451. VAN DEN HEUVEL T, Bijnens E, Verhaegh B, Nawrot T, et al
    P690 Ambient air quality does not affect disease course in inflammatory bowel disease - a population based risk factor analysis using geographic information systems.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  452. HUH G, Yoon H, Choi YJ, Park YS, et al
    P715 Trends in emergency department visits and hospitalization rates for inflammatory bowel disease: results from a single-center in 2004, 2009 and 2014.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  453. JUZENAS S, Skieceviciene J, Salteniene V, Kupcinskas J, et al
    P759 MiRNA expression patterns in colon of active and inactive ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  454. PERDIGOTO D, Portela F, Ferreira M, Mendes S, et al
    P600 Infliximab trough levels for remission induction and long term therapy management of inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  455. WEISSHOF R, Aharoni Golan M, Masching A, Rubin DT, et al
    P619 Tofacitinib for the treatment of resistant ulcerative colitis: the University of Chicago experience.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  456. VANCAMELBEKE M, Sabino J, Deroover L, Vandermeulen G, et al
    P774 Metagenomics and metabolomics of patients with inflammatory bowel disease and their unaffected relatives.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  457. PASCHOS P, Katsoula A, Giouleme O, Tsapas A, et al
    P662 Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  458. BROLY F, Fumery M, Vasseur F, Savoye G, et al
    P756 Diagnosing rare inherited disorders using targeted next generation sequencing in patients with early-onset inflammatory bowel disease: a population-based study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  459. JUAN G, Alvarino A, Mora M, Oltra L, et al
    P557 Utility of "trough levels" adalimumab determination in patients with inflammatory bowel disease. Estimation of individual pharmacokinetic parameters through population pharmacokinetic model.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  460. PEERANI F, Chang H, Ungaro R, Torres J, et al
    P705 Peripheral arterial disease is associated with an increased risk of elderly-onset inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  461. OPSTELTEN J, Chan S, Hart A, van Schaik F, et al
    P722 Prediagnostic serum vitamin D levels and risk of inflammatory bowel disease: a pan-European, nested case-control study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  462. GOBBO MONTOYA M, Marin-Jimenez I, Panadero A, Modino Y, et al
    P736 Psychological impact of inflammatory bowel disease: differences by gender and age. The ENMENTE Project.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  463. WILLEMZE R, Bakker T, Pippias M, Ponsioen C, et al
    P716 Beta-blocker use is associated with a higher relapse risk of inflammatory bowel disease - a Dutch retrospective cohort study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  464. BURISCH J, Halfvarson J, Kupcinskas L, Hernandez V, et al
    P695 The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort - the ECCO-EpiCom cohort.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  465. WATTS G, Arasaradnam R, Travis S, Sharma A, et al
    P512 Real world use of adalimumab: effects on corticosteroid treatment and hospital resource utilisation in UK patients with moderate/severe ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  466. KAMPERIDIS N, O'Connor M, Crook K, Arebi N, et al
    P490 A pilot study of the electronic patient portal "Patient Knows Best" for monitoring biologic therapy in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  467. YAMAMOTO T, Shimoyama T, Umegae S
    P497 Impacts of mucosal healing on clinical outcomes in patients with refractory ulcerative colitis on tacrolimus or biologics.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  468. RUBIN DT, Panes J, Lindsay JO, Vermeire S, et al
    P558 The SF-36(R) Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  469. GUERRERO PUENTE LN, Iglesias Flores E, Benitez Cantero JM, Cardenas Aranzana MJ, et al
    P545 Clinical outcomes following a switch from Remicade(R) to the biosimilar CT-P13 in inflammatory bowel disease patients in clinical remission: preliminary results.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  470. SMITS L, Grelack A, Drenth J, de Jong D, et al
    P663 Switching from Remicade(R) to biosimilar CT-P13 in inflammatory bowel disease patients: one year follow-up of a prospective observational cohort study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  471. HUOPONEN S, Eberl A, Rasanen P, Roine RP, et al
    P685 Switching from originator-infliximab to biosimilar-infliximab has no influence on health-related quality of life and clinical disease activity among patients with inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  472. MAKARCHUK P, Belousova E, Volchkova E, Kudriavtseva E, et al
    P517 Features of cytomegalovirus infection in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  473. SAMBUELLI A, Bellicoso M, Negreira S, Goncalves S, et al
    P585 Infliximab in moderate to severe ulcerative colitis: comparison between scheduled treatment strategy and bridge strategy.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  474. BAKER D, Marshall J, Lee M, Jones G, et al
    P443 Systematic review of internet decision making resources for patients considering surgery for ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  475. CHADOKUFA S, Sider S, Huggett B, Sawney T, et al
    P591 Therapeutic drug monitoring in Paediatric inflammatory bowel disease on maintenance infliximab and adalimumab treatment improves clinical remission with a proactive approach.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  476. DE BRUYN M, Ringold R, Ferrante M, Van Assche G, et al
    P382 A panel of serum markers for early detection of endoscopic healing with infliximab in patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  477. BOSSA F, Valvano MR, Costantino G, Vinci E, et al
    P621 Efficacy and safety of golimumab in ulcerative colitis. Preliminary data from a multicenter Italian study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  478. CAGOL L, Frivolt K, Krahl A, Forster N, et al
    P486 Immunization status of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  479. LOPETUSO LR, Petito V, Graziani C, Scannone D, et al
    P498 Emerging role of the IL-33/ST2 axis in predicting mucosal response to anti-TNF therapy in ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  480. SANDBORN WJ, Rutgeerts P, Zhang H, Adedokun OJ, et al
    P446 Characterization of ulcerative colitis patients in the Golimumab PURSUIT-Maintenance study: post-hoc analyses of patients who maintained and did not maintain clinical response through week 54.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  481. KANG B, Choi JY, Lee K, Lee SY, et al
    P755 NUDT15 polymorphism is associated with thiopurine-related leukopenia independently of 6-thioguanine nucleotide levels in Korean paediatric inflammatory bowel disease patients.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  482. PANES J, Rubin DT, Vermeire S, Lindsay JO, et al
    P467 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  483. ORDAS I, Domenech E, Aguas M, Fernandez-Banares F, et al
    P607 Post-operative mortality and predictive factors in a cohort of severe refractory ulcerative colitis patients from the ENEIDA Registry (1989-2013): a multicenter nationwide study.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  484. BEN-HORIN S, Andrews JM, Katsanos KH, Rieder F, et al
    P341 Combination of corticosteroids and 5-aminosalycilates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physicians' practice.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  485. PAUWELS RW, De Vries AC, Van der Woude CJ
    P447 Vedolizumab induces significantly higher endoscopic remission rates at week 16 in ulcerative colitis as compared to Crohn's disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  486. BASTIDA G, Sargalt L, Garcia V, Mesonero F, et al
    P528 Long-term outcome of ulcerative colitis patients responders to cyclosporine in the biological era.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  487. DANESE S, Gisbert JP, Lobo AJ, Dignass A, et al
    P328 Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease: findings from a European online survey.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  488. THI AA, Bouri S, Wolfson P, Owen L, et al
    P439 Diagnosis and management of latent and active tuberculosis in the context of biologic therapy in inflammatory bowel disease.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  489. LEFEVRE C, Fotsing G, Wangermez M, Beau P, et al
    P396 Long-term efficacy of thiopurines as maintenance treatment in 130 patients with ulcerative colitis.
    J Crohns Colitis. 2017;11.
    PubMed     Text format    


  490. GIONCHETTI P, Dignass A, Danese S, Magro Dias FJ, et al
    3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations.
    J Crohns Colitis. 2017;11:135-149.
    PubMed     Text format     Abstract available


  491. KIM HJ, Oh SH, Kim DY, Lee HS, et al
    Clinical Characteristics and Long-Term Outcomes of Paediatric Crohn's Disease: A Single-Centre Experience.
    J Crohns Colitis. 2017;11:157-164.
    PubMed     Text format     Abstract available


  492. VIRTA LJ, Saarinen MM, Kolho KL
    Inflammatory Bowel Disease Incidence is on the Continuous Rise Among All Paediatric Patients Except for the Very Young: A Nationwide Registry-based Study on 28-Year Follow-up.
    J Crohns Colitis. 2017;11:150-156.
    PubMed     Text format     Abstract available


  493. LIGHTNER AL, Raffals LE, Mathis KL, Cima RR, et al
    Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:185-190.
    PubMed     Text format     Abstract available


  494. WILLIET N, Sarter H, Gower-Rousseau C, Adrianjafy C, et al
    Patient-reported Outcomes in a French Nationwide Survey of Inflammatory Bowel Disease Patients.
    J Crohns Colitis. 2017;11:165-174.
    PubMed     Text format     Abstract available


  495. HART AL, Lomer M, Verjee A, Kemp K, et al
    What Are the Top 10 Research Questions in the Treatment of Inflammatory Bowel Disease? A Priority Setting Partnership with the James Lind Alliance.
    J Crohns Colitis. 2017;11:204-211.
    PubMed     Text format     Abstract available


  496. JAIRATH V, Levesque BG, Vande Casteele N, Khanna R, et al
    Evolving Concepts in Phases I and II Drug Development for Crohn's Disease.
    J Crohns Colitis. 2017;11:246-255.
    PubMed     Text format     Abstract available


  497. SUZUKI K, Yokoyama J, Kawauchi Y, Honda Y, et al
    Phase 1 Clinical Study of siRNA Targeting Carbohydrate Sulphotransferase 15 in Crohn's Disease Patients with Active Mucosal Lesions.
    J Crohns Colitis. 2017;11:221-228.
    PubMed     Text format     Abstract available


  498. DEVRIESE S, Eeckhaut V, Geirnaert A, Van den Bossche L, et al
    Reduced Mucosa-associated Butyricicoccus Activity in Patients with Ulcerative Colitis Correlates with Aberrant Claudin-1 Expression.
    J Crohns Colitis. 2017;11:229-236.
    PubMed     Text format     Abstract available


  499. WRIGHT EK, Kamm MA, Wagner J, Teo SM, et al
    Microbial Factors Associated with Postoperative Crohn's Disease Recurrence.
    J Crohns Colitis. 2017;11:191-203.
    PubMed     Text format     Abstract available


  500. LEMMENS B, de Buck van Overstraeten A, Arijs I, Sagaert X, et al
    Submucosal Plexitis as a Predictive Factor for Postoperative Endoscopic Recurrence in Patients with Crohn's Disease Undergoing a Resection with Ileocolonic Anastomosis: Results from a Prospective Single-centre Study.
    J Crohns Colitis. 2017;11:212-220.
    PubMed     Text format     Abstract available


  501. KATSANOS KH, Domenech E, Rahier JF, Kopylov U, et al
    Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics.
    J Crohns Colitis. 2017;11:256-257.
    PubMed     Text format    


  502. WONG DR, Coenen MJ, Vermeulen SH, Derijks LJ, et al
    Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:175-184.
    PubMed     Text format     Abstract available


    January 2017
  503. HARBORD M, Eliakim R, Bettenworth D, Karmiris K, et al
    Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.
    J Crohns Colitis. 2017 Jan 28. doi: 10.1093.
    PubMed     Text format    


  504. RAZANSKAITE V, Bettey M, Downey L, Wright J, et al
    Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    J Crohns Colitis. 2017 Jan 27. pii: jjw216. doi: 10.1093.
    PubMed     Text format     Abstract available


  505. DANESE S, Fiorino G, Raine T, Ferrante M, et al
    ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
    J Crohns Colitis. 2017;11:26-34.
    PubMed     Text format    


  506. SHINZAKI S, Matsuoka K, Iijima H, Mizuno S, et al
    Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.
    J Crohns Colitis. 2017;11:84-91.
    PubMed     Text format     Abstract available


  507. GOMOLLON F, Dignass A, Annese V, Tilg H, et al
    3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.
    J Crohns Colitis. 2017;11:3-25.
    PubMed     Text format     Abstract available


  508. DETREZ I, Gils A
    Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    J Crohns Colitis. 2017;11:1-2.
    PubMed     Text format    


  509. PEYRIN-BIROULET L, Lonnfors S, Roblin X, Danese S, et al
    Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations.
    J Crohns Colitis. 2017;11:128-133.
    PubMed     Text format     Abstract available


  510. ROBBINS L, Zaghiyan K, Melmed G, Vasiliauskas E, et al
    Outcomes with Anti-Tumour Necrosis Factor-Alpha Therapy and Serology in Patients with Denovo Crohn's Disease After Ileal Pouch Anal Anastomosis.
    J Crohns Colitis. 2017;11:77-83.
    PubMed     Text format     Abstract available


  511. ADEDOKUN OJ, Xu Z, Marano CW, Strauss R, et al
    Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    J Crohns Colitis. 2017;11:35-46.
    PubMed     Text format     Abstract available


  512. SIMON M, Cosnes J, Gornet JM, Seksik P, et al
    Endoscopic Detection of Small Bowel Dysplasia and Adenocarcinoma in Crohn's Disease: A Prospective Cohort-Study in High-Risk Patients.
    J Crohns Colitis. 2017;11:47-52.
    PubMed     Text format     Abstract available


  513. PAPAMICHAEL K, Baert F, Tops S, Assche GV, et al
    Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.
    J Crohns Colitis. 2017;11:53-59.
    PubMed     Text format     Abstract available


  514. HERNANZ N, Lopez-Sanroman A
    A Pitfall to Avoid: Hyperlipasemia, Azathioprine, and Autoimmune Pancreatitis.
    J Crohns Colitis. 2017;11:134.
    PubMed     Text format    


  515. HOOPER KM, Barlow PG, Stevens C, Henderson P, et al
    Inflammatory Bowel Disease Drugs: A Focus on Autophagy.
    J Crohns Colitis. 2017;11:118-127.
    PubMed     Text format     Abstract available


  516. CHEN W, Lu C, Hirota C, Iacucci M, et al
    Smooth Muscle Hyperplasia/Hypertrophy is the Most Prominent Histological Change in Crohn's Fibrostenosing Bowel Strictures: A Semiquantitative Analysis by Using a Novel Histological Grading Scheme.
    J Crohns Colitis. 2017;11:92-104.
    PubMed     Text format     Abstract available


  517. KAMMERMEIER J, Dziubak R, Pescarin M, Drury S, et al
    Phenotypic and Genotypic Characterisation of Inflammatory Bowel Disease Presenting Before the Age of 2 years.
    J Crohns Colitis. 2017;11:60-69.
    PubMed     Text format     Abstract available


  518. JOSHI NM, Marks IH, Crowson R, Ball D, et al
    Incidence and Outcome of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease in the UK.
    J Crohns Colitis. 2017;11:70-76.
    PubMed     Text format     Abstract available


    November 2016
  519. EBERHARDSON M, Karlen P, Linton L, Jones P, et al
    Randomised, Double-blind, Placebo-controlled Trial of CCR9-targeted Leukapheresis Treatment of Ulcerative Colitis Patients.
    J Crohns Colitis. 2016 Nov 2. doi: 10.1093.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: